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ACRONYMS AND ABBREVIATIONS 
ADE  Adverse Drug Events 
CAP  Community-acquired pneumonia 
CBC  Complete blood count 
CBA  Cost-benefit analysis 
CEA  Cost-effectiveness analysis 
CMA  Cost-minimization analysis 
COPD  Chronic obstructive pulmonary disease 
CUA  Cost-utility analysis 
DM  Diabetes mellitus  
ESBL  Extended-spectrum beta-lactamase  
FDA  (United States) Food and Drug Administration 
GW  General ward 
IAI  Intra-abdominal infection 
IC  Imipenem/Cilastatin 
IDSA  Infectious Disease Society of America 
ITT  Intention to treat 
LFT  Liver function test 
LOAS  Length of antibiotic stay 
LRTI  Lower respiratory tract infection 
KAH  King Abdulaziz Hospital 
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MIC  Minimum inhibitory concentration  
MEM  Meropenem 
MONG Ministry of National Guard 
MRSA  Methicillin-resistant Staphylococcus aureus 
NHS  National Institute for Health Research 
NNIS  National Nosocomial Infection Surveillance 
PI  Principal investigator 
PT  Prothrombin time 
PTC  Pharmacy and Therapeutics Committee 
PTT  Partial thromboplastin time 
RCT  Randomised controlled trials 
SFDA  Saudi Food and Drug Authority 
SSI  Skin and skin structure infection  
UTI  Urinary tract infection 
q8h  Every 8 hours 
q6h  Every 6 hours 
q12h  Every 12 hours 
QALY  Quality-adjusted life years 
SAR  Saudi Arabian Riyal 






Introduction: The aim of this study was to compare the costs of management of moderate to 
severe infections in patients treated with imipenem/ cilastatin (IC) and meropenem (MEM). 
Pharmacoeconomic studies in Saudi Arabia are scarce. Available hospital data illustrate that 
carbapenem antibiotics are among the most expensive medicines being procured. The current 
hospital formulary at the King Abdulaziz National Guard Hospital, Al-Ahsa, Saudi Arabia, 
contains 2 carbapenems: IC and MEM. These antibiotics share a similar spectrum of activity, 
with the unit cost of IC (500mg/ 500mg) being less than that for MEM (1 gram). There are 
conflicting reviews with regard to the relative cost-effectiveness of these 2 agents.  An 
unpublished pharmacoeconomic review at our institute has shown that an interchange 
programme substituting MEM with IC would lead to a cost saving of SAR2 306 257 per year. 
Methods: A retrospective, single-centre cohort study of 88 patients, applying cost-minimization 
analysis, of IC versus MEM in moderate to severe infections was conducted at the King 
Abdulaziz National Guard Hospital, Al-Ahsa. In accordance with cost-minimization analysis 
methods, the assumption of equivalent efficacy was demonstrated by literature retrieved and 
cited. Direct costs related to the management of the infections were included in the study. Adult 
patients (≥ 18 years old) diagnosed with moderate to severe infection, including skin and skin 
structure infections (SSIs), sepsis, intra-abdominal infections (IAIs), respiratory tract infections, 
urinary tract infections (UTIs) and hospital-acquired infections (HAIs), who were prescribed IC 
500mg every six hours intravenously (2 gram per day) or MEM 1 gram every eight hours (3 
gram per day), were included in the study.  
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Results: Overall there was no difference in the mean total daily costs between IC (SAR 4 784.46, 
95% CI 4 140.68, 5 428.24) and MEM (4 390.14, 95% CI 3 785.82, 4 994.45;, p = 0.37). The 
study showed no significant difference in terms of mean daily critical care hospital stay costs. 
Mean general ward costs were significantly lower in the IC group. Significantly lower medicine 
acquisition vial cost of IC was observed when compared to MEM, however there was a 
significantly higher cost attached to administration sets used in the IC group than the MEM 
group. Consultation, nursing and physician costs were not significantly different between the 
groups. No differences were observed in costs associated with adverse drug events (ADEs).  
Conclusion: This study has shown that while acquisition costs of IC at a dose of 500mg q6h may 
be lower than for MEM 1 gram q8h, mean total costs per day were not significantly different 
between IC and MEM, indicating that medicine costs are only a small element of the overall 
costs of managing moderate to severe infections. Enforcing the Pharmacy and Therapeutic 
Committee (PTC) recommendations will assist in selecting the most appropriate carbapenem, 
while at the same time minimize drug costs. Further pharmacoeconomic research within the 
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CHAPTER 1: INTRODUCTION 
1.1. Introduction 
As in almost every health system, medication costs at the King Abdulaziz Hospital (KAH) have 
increased noticeably over time. High prices of essential medicines are a heavy burden on the 
government budget. Policymakers are in search of the most cost-effective options for the 
government and society as a whole.  
Available hospital data show that the carbapenem antibiotics were the third most expensive 
pharmacological class procured during the 2009. The current hospital formulary lists two 
carbapenems: the fixed-dose combination of imipenem/cilastatin (IC) and meropenem (MEM). 
MEM is restricted to infection control physicians, while IC is restricted to infection control, 
intensivists and haematology/oncology practitioners. These antibiotics share a similar spectrum 
of activity, but the unit cost of IC (500mg/500mg) is less than that for the equipotent dose of 
MEM (1g). There are conflicting reviews with regard to the relative cost-effectiveness of these 
two medicines (1, 2).  
There have been considerable differences in prescribing patterns among local physicians at 
KAH. Hospital usage data indicate that MEM is prescribed much more frequently than IC. 
Partly, this may be related to the concern about seizures associated with the use of IC (3). IC has 
been used for more than 20 years, and has an extensive range of approved indications. IC may 
therefore be an attractive choice in terms of acquisition cost.  
An unpublished pharmacoeconomic review at KAH has shown that an interchange programme, 
substituting MEM with IC, would lead to a cost saving of Saud Arabian Riyals 
(SARs) 2 306 257 per year. Hospital antimicrobial usage data since 2004 shows that IC usage is 
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significantly lower than MEM. This has had a considerable impact on the hospital budget. There 
have been limited applications of pharmacoeconomic evaluations in Saudi Arabia (4). It would 
be most appropriate to test the economic impact of the proposed substitution as well as the main 
factors influencing hospital costs, in this setting, based on pharmacoeconomic principles. In this 
regard, a cost-minimization analysis could provide an estimate of the economic impact of these 
therapeutically equivalent medicines, focusing on local Saudi Arabian data. 
 
1.1.1. Aim:  
To contribute to the rational selection of medicines, in order to achieve efficiencies and better 
patient outcomes, by focusing on high-cost medicines used in the Saudi Arabian health system. 
 
1.1.2. Objectives: 
1. To conduct a cost-minimization analysis of the cost of management of moderate to severe 
infections in adult patients treated with either imipemen-cilastatin or meropenem in a 
Saudi Arabian tertiary hospital. 
2. To determine whether the existing antimicrobial interchange protocol was appropriate, in 
the light of the direct costs incurred for patient care. 





In Saudi Arabia, the population of 27 million has access to over 400 hospitals, 2075 health care 
centres and 850 private clinics. Medicine costs have been increasing substantially over time, with 
an estimated total national expenditure of SAR 13.9 billion ($3.7 billion) in 2013 (5). Health care 
in Saudi Arabia is predominantly provided by the government (public) sector. This includes the 
Ministry of National Guard, Ministry of Health, Ministry of Defence and Ministry of Higher 
Education (through the University-associated hospitals) (6).  
The Ministry of National Guard (MONG) provides free health care to members of the National 
Guard and their dependents. MONG operates 5 hospitals with almost 3000 beds in total. 
Unofficial reports estimate the total medicine expenditure at these MONG facilities to be 
approximately SAR 1 billion per annum.  
In 2012, total annual expenditure on MEM at KAH placed it in the top 10 medicines at the 
institution in value terms. Data on carbapenem utilisation in the KAH intensive care unit (ICU) 
for 2009 was compared to similar figures reported in the United States National Nosocomial 
Infection Surveillance (NNIS) report for 2004 (7). Usage was measured in defined daily doses 
(DDDs) per 1000 patient days (7). The NNIS report interprets any result above the 90th 
percentile as a higher outlier, which indicates a problem in terms of usage. Usage at KAH in 
2009 extended into the 90th percentile of US usage, as measured in 2004, as shown in Figure 1. 
This can be interpreted as indicative of excessive use of the carbapenem group as a whole, in 




Figure 1 - Carbapenem usage at King Abdulaziz Hospital (KAH) 
 
 
The Department of Infection Control, Department of Microbiology and Pharmacy attempted to 
minimise usage of MEM by suppressing mention of this agent in sensitivity reports appearing in 
the hospital’s electronic health information system. If MEM was sensitive to the causative 
organism, the health information system would not suggest MEM as a treatment option to 
prescribers; however it would report other alternative antibiotics that are sensitive to the 
organism. In the case where there are no alternatives, then only would the sensitivity reports 
disclose MEM as the drug of choice. This was implemented in an attempt to encourage usage of 
alternative antibiotics, including IC. The Pharmacy and Therapeutics Committee (PTC) also 
restricted the use of MEM to infection control practitioners only. IC was restricted to infection 
control, intensivists and haematology/oncology practitioners. The Infection Control Department 
developed usage guidelines for IC and MEM. It was projected that the institute could save more 
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subsequently reviewed the usage of IC in the intensive care unit, using the approved guidelines. 
These interventions have assisted in the rational use of some of the most expensive antibiotics, 
especially in the intensive care unit. The unpublished pharmacoeconomic review examined the 
acquisition costs of the study drugs and did not include resource costs associated with the 
primary infection. A cost-minimization analysis is therefore proposed in an attempt to investigate 
overall costs between these two clinically equivalent drugs.  
1.2.1. Pharmaceutical Expenditure in Saudi Arabia 
Saudi Arabia is the largest oil producer in the world, and is considered affluent enough to meet 
its health expenditure bill comfortably. However, an increase in health care demand in any 
country places stress on the ability of that government to cover the financial costs. In a country 
where citizens do not pay taxes and rely on the government to pay the totality of all health care 
costs, considerations of cost-effectiveness and value-for-money need to be prioritised, 
Pharmacoeconomics could play an important role in guiding hospital formularies in selecting 
cost-effective therapies. It may seem that there are limited restrictions to health care budgets in 
Saudi Arabia; however it seems inevitable that the country will increasingly look for strategies to 
minimise expenses as demands on the fiscus increase. 
In 2010, the population in Saudi Arabia was reported to be 27 136 977, with an annual 
population growth rate of 3.2% (6). The Gross Domestic Product (GDP) growth rate was 4.15% 
in 2010. Life expectancy at birth is 72.6 years for males and 74.9 years for females. Infectious 
and parasitic diseases are the sixth most important cause of death (6), after:- 
1. accident, injury, poison, and external reason; 
2. circulatory system disease; 
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3. certain cases arising in the perinatal period; 
4. respiratory disease; and 
5. tumours. 
 Approximately 69% of the population receives free medical care from the government sector 
(6). The total annual health expenditure in 2009 was SAR 72.3 billion.  In 2010, pharmaceutical 
expenditures were reported to be SAR 13.5 billion. Pharmaceutical expenditure makes up 18% 
of the total health expenditure (6).  
Saudi Arabia is a member of the World Trade Organization and is therefore a signatory of the 
Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). Patents on 
pharmaceutical products are therefore routinely exercised in Saudi Arabia, limiting early access 
to generic medicines except in the case of deliberate licensing by the patent-holder. There are 
approximately 19 licensed pharmaceutical manufacturers in Saudi Arabia. However both IC and 
MEM are imported into the country as finished pharmaceutical products. IC is imported from the 
Netherlands and MEM from Italy. The local supplier (Al-Naghi) bears the responsibility for 
importation of both of these products. Under Saudi law, the medicines regulatory authority, the 
Saudi Food and Drug Authority (SFDA), also controls medicine pricing. Control of pricing 
includes pharmaceutical companies’ factory costs at the country of origin, plus insurance and 
freight charges (8). IC was priced at SAR 70.40 (for imipenem 500mg/cilastatin 500mg) on the 
SFDA human price list for October 2013, while MEM was priced at SAR 151.26 (for 
meropenem 1g) (8). 
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1.2.2 Pharmacoeconomic principles 
Health care has become a challenging environment for professionals, in trying to achieve the 
highest quality of care based on sound evidence-based principals. However, rising health care 
costs may hinder best practices. In a cost-sensitive culture, pharmacoeconomics may shed light 
on the value achieved for a set investment. Applications of pharmacoeconomics must be based 
on a clear understanding so as to ensure that the findings enable effective interventions, such as 
in the field of medicines selection.  
The field of pharmacoeconomics identifies the costs and consequences of alternative medicines 
therapy in order to make the best possible decision, while ensuring the maximum benefit and 
efficiency of budgets or resources (9). Pharmacoeconomics utilises sound evidence-based 
principles by comparing benefits in terms of the resources available. It attempts to quantify the 
value of pharmaceutical care and services. As two or more agents are being compared, it is 
essential to consider the relative efficacy and safety of these options. The four main forms of 
pharmacoeconomic analyses are cost-effectiveness analysis (CEA), cost-utility analysis (CUA), 
cost-benefit analysis (CBA) and cost-minimization analysis (CMA). 
In a CEA, the relative costs and effects of two or more courses of action are measured. The 
effects are measured in natural units, such as years of life gained or symptom free days (9). 
Generally speaking, CEA could be used to determine if an additional budget is worth the 
additional benefit of the competing option (be that a medicine or other health care intervention) 
(10). However such studies have received criticism due to the interpretation of these ‘effects’ (9). 
Critically, one of the agents must be therapeutically superior to the other and more expensive. 
The incremental cost of achieving the additional benefits associated with the more expensive 
option are determined, and compared with a pre-determined cost-effectiveness threshold. In a 
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CUA the consequences are combined in a single generic measure such as quality adjusted life 
years (QALY) gained, cost per healthy year equivalent or cost per disability adjusted life year 
(DALY) (11). The term ‘utility’ has not been precisely defined. However in practice it may be 
thought of as an interval scale measuring the strength of preference for a given health state (11).  
A utility may be represented by a number measuring the intensity of preference, where full 
health is given the utility 1 and death 0. The methods used in estimating utilities have been much 
debated (11). In a CBA, the consequences are measured in terms of money (9). With CBA, 
studies apply a monetary value to outcomes, facilitating comparisons between health and non-
health programmes (11). In all pharmacoeconomic analyses, generalisability may be limited by 
the reliance on local data.  
In this study, a CMA approach was selected, which assumes that the consequences are clinically 
equivalent and then determines the least costly alternative (12). The assumption that both IC and 
MEM are clinically equivalent in terms of safety and efficacy will be tested in the literature 
review section. A CMA can only be performed if two interventions produce the same clinical 
effect (12). The prospective, randomized, controlled trial (RCT) is considered the ‘gold standard’ 
when comparing two interventions (12). The assumption of clinical efficacy and safety 
equivalency between IC and MEM was tested in the literature review section. Studies on the 
local population may be more applicable to the context of Saudi Arabia and hence a study of this 
nature was considered. 
Assessing the costs and consequences depends on the perspective of the study. The patient 
perspective includes the costs that the patient pays for a product or service. The consequence 
includes the clinical effects. The societal perspective considers the benefits to society and thus 
measures both direct and indirect costs associated with the treatment. In the payer perspective, 
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often relied upon by government institutions, the costs are represented by the costs of delivering 
the health services or products allowed or reimbursed. This study utilizes the perspective of the 
payer (government) in terms of both costs and consequences. The costs include direct medical 
costs only. Direct medical costs include the costs of medicines, laboratory tests, health care 
provider costs, hospitalization costs, supplies and administration costs. Direct non-medical costs 
(transportation and food), indirect medical costs (lost income) and intangible costs (pain and 
suffering) are not considered in a payer perspective analysis. Figure 2 outlines the basic concept 
of the economic evaluation conducted. Here IC and MEM are being compared in terms of 
success and failure. This is followed by a costing analysis. The objective is to find the least 
costly alternative. 
 
Figure 2 - Economic evaluation of costs and outcomes 
 
Key: IC = imipenem/cilastatin; MEM = meropenem 
Although pharmacoeconomic models may provide valuable input to guide medicines selection 
decisions, several uncertainties may remain. In this regard a sensitivity analysis may explore if 
the conclusions of the study are dependent upon underlying assumptions or errors in 











one parameter on the conclusions of the study. In this case one variable is varied while the others 
are kept at their baseline value. This can allow the researcher to assess which parameters are 
likely to have the greatest influence on the conclusions reached. These results can be expressed 
graphically in the form of a tornado diagram. A multi-way sensitivity analysis examines the 
relationship of 2 or more parameters on the conclusions of the study. This can be represented in a 
graph, plotting the input and output of the results. In this way a researcher could find the 
threshold at which the conclusion changes (14).  
1.3. Clinical Pathology and Management 
Management of a primary infection must be based on clear understanding of the pathology and 
the clinical course of the disease. The KAH Infection Control and Prevention Department has 
provided guidelines for the use of IC and MEM (15). In this study the comparative efficacy and 
safety of IC to MEM was assessed on the basis of the available literature. This Introductory 
section provides a brief explanation of the conditions for which these antibiotics are used. 
1.3.1. Intra-abdominal Infection (IAI): 
IAI has been described as an abscess or peritonitis affecting several areas of the gastrointestinal 
tract. This is generally due to infiltration of bacteria in the wall of a hollow viscus or beyond 
(16). Common sites include the stomach, biliary tract, duodenum, pancreas, appendix, small 
intestine and the colon (17). Clinical presentation includes rapid onset of abdominal pain and 
symptoms of gastrointestinal dysfunction. Definitions remain unclear, however. Uncomplicated 
IAI usually refers to inflammation or infection of the wall of an abdominal organ. If not treated 
appropriately, it can lead to complicated IAI (16). Most of the complicated IAIs involve 
peritonitis or intra-abdominal abscesses (16). The Infectious Disease Society of America (IDSA) 





Microbiology of IAI 
The causative organisms of IAI are largely related to the resident gastrointestinal flora (16). 
Treatment should target Gram-negative aerobic and facultative bacilli, anaerobes as well as β-
lactam-susceptible Gram-positive cocci (19). Common pathogens include Escherichia coli, 
Klebsiella species, Pseudomonas aeruginosa, Proteus mirabilis, Enterobacter species, 
Bacteroides fragilis, Clostridium species, Prevotella species, Streptococcus species, and 
Enterococcus species (18). IAI developing from perforations of the gastrointestinal tract or any 
of its appendages are mainly polymicrobial. Nosocomial pathogens in the health care setting 
make patients particularly susceptible , and such infections may further be complicated by fungal 
infections, especially Candida species (16). In obstructive disorders for distal small bowel, 
colon-derived infections and proximal small bowel perforations, therapy should include agents 
effective against obligate anaerobic bacilli (19). In the case of hospital-acquired infections, local 
pathogen sensitivity and resistance patterns should be considered.  
Treatment of IAI 
Interventions include drainage of the abscess or infected fluid collections, surgical intervention, 
as well as pharmacological management. Early appendectomy has been considered essential , 
although some experts opt for non-surgical intervention with antibiotic management (16). 
Treatment of diffuse peritonitis and patients with septic shock may be more complex (16).  
The goal of antimicrobial therapy is to target the resident organisms as described above. 
Carbapenems provide a broad spectrum of coverage making them suitable for IAI. β-lactam/β-
lactamase inhibitor combinations such as piperacillin/tazobactam or ampicillin/sulbactam could 
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be used. Cephalosporins with anaerobic cover include cefotetan and cefoxitin. Fluoroquinolones 
could include moxifloxacin. Other regimens have included tigecycline, cephalosporin-based 
regimens, monobactams and aminoglycosides. Several studies have demonstrated the efficacy of 
carbapenems (IC and MEM) in IAI. These studies will be discussed in the literature review 
section below (16). 
1.3.2. Skin and Skin Structure Infections (SSI): 
SSIs are responsible for about 10% of hospital admissions in the United States (20). They may 
be uncomplicated or complicated. Uncomplicated SSIs include impetigo, abscesses, furuncles 
and cellulitis (20). SSIs are considered complicated when they involve deep structures, involve 
patients with comorbidities like diabetes mellitus (DM), immunocompromised patients, or 
require surgical intervention (21). This may include major abscesses, infected burns and ulcers, 
infected bite wounds and diabetic foot infections (20). Clinical presentation may include pain, 
fever, hypothermia, tachycardia hypotension, violaceous bullae, cutaneous haemorrhage, skin 
anaesthesia and gas in the tissue (22). Infections may include abscess, impetigo and cellulitis, 
necrotizing infections, surgical site infections, immunocompromised-associated infection and 
animal-contact-with-human skin-associated infections (22).  
Microbiology of SSI 
Treatment should target Staphylococcus aureus, Streptococcus pyogenes, Pseudomonas 
aeruginosa, and Enterococcus species. Recently methicillin-resistant Staphylococcus aureus 





Treatment of SSI 
First-line agents include cephalosporins, such as cephalexin and cefdinir, or penicillins such as 
cloxacillin. Newer generation fluoroquinolones, such as moxifloxacin and gatifloxacin, may be 
used. In complicated SSI, aggressive treatment is necessary, making the broad spectrum 
carbapenems an appropriate choice (20). 
1.3.3. Lower Respiratory Tract Infection (LRTI): 
LRTIs are infections involving the airway and lungs that include pneumonia, bronchitis, 
bronchiolitis and tuberculosis. LRTIs may present as acute bronchitis, influenza, community-
acquired pneumonia (CAP), acute exacerbation of chronic obstructive pulmonary disease 
(COPD) and acute exacerbation of bronchiectasis (23). Acute LRTI usually presents as a cough 
with secondary symptoms that could include sputum production, dyspnoea, wheeze or chest 
discomfort and pain (23). IDSA has developed a comprehensive set of guidelines to assist in 
hospital-based management. Severity of illness scores modified to the hospital setting may also 
be utilised. In community-acquired pneumonia (CAP), an example is the CURB-65 criteria 
(confusion, uraemia, respiratory rate, low blood pressure, and age above 65). With scores ≥ 2, 
intensive home health care is needed, while patients in septic shock require direct ICU 
admission. Diagnostic testing includes chest radiograph or other imaging demonstrating 
infiltrates. Blood, endotracheal fluid and sputum cultures are recommended. Consideration 
should be given to aspiration pneumonia, left ventricular failure, and pulmonary embolism 
during the differential diagnosis. 
Microbiology of LRTIs 
Treatment should target Gram-negative pathogens, Staphylococcus aureus, Pseudomonas 
aeruginosa, Streptococcus pneumoniae, Acinetobacter species, Mycobacterium tuberculosis, 
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Haemophilus influenzae, Legionella species, Moraxella catarrhalis, and Chlamydia species (23). 
In recent years MRSA has been implicated in LRTIs.  
Treatment of LRTIs 
Early antibiotic treatment should be considered. Suitable choices include a penicillin with or 
without macrolides or quinolones. The newer higher penicillin dosing available (such as 
amoxicillin-clavulanic acid 2000mg/125mg) may prove advantageous. Quinolones with activity 
against Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus and 
Moraxella catarrhalis are now an established treatment in LRTIs. Carbapenems provide a broad 
spectrum of activity and an appropriate choice for treatment in limited circumstances (23). Their 
usage would be limited to instances of failure of first-line penicillins, such as penicillin 
resistance, as they are the most active beta-lactams that counter penicillin-resistant Streptococcus 
pneumonia (23). 
1.3.4. Urinary Tract Infection (UTI) 
UTIs in adults are a group of disorders affecting the bladder, kidney, urethra and ureter. High-
risk groups include sexually active women, the elderly, diabetics, and those undergoing a 
surgical procedure. Patients present with fever, pain in the lower abdomen, dysuria and increased 
frequency of urination. Computerised tomography (CT) scan, intravenous pyelogram, urine 
culture and urinalysis may be done to confirm diagnosis.  UTIs have been classified as acute 
uncomplicated cystitis, recurrent cystitis in young women, acute cystitis in young men, acute 
uncomplicated pyelonephritis, complicated UTI, asymptomatic bacteriuria in pregnancy and 




Microbiology of UTIs 
Causative pathogens may include Escherichia coli, Staphylococcus species, Proteus mirabilis, 
Klebsiella pneumoniae, Enterococcus species, and Pseudomonas aeruginosa (24). 
 
Treatment of UTIs 
Treatment may range from simple hygiene interventions to surgical interventions or antibiotic 
therapy. Pharmacotherapy for acute uncomplicated UTI usually includes trimethoprim-
sulfamethoxazole, fluoroquinolones, amoxicillin, cephalosporin (such as ceftriaxone), or 
nitrofurantoin. For recurrent cystitis, prophylactic treatment is warranted. Carbapenems offer a 
broad spectrum of activity which may prove effective in complicated UTIs, as they are active 
against organisms associated with some nosocomial UTIs (24, 25). 
1.3.5. Sepsis 
Sepsis is defined as an inflammatory response to infection. It could occur as a result of multiple 
causes and infections (26). Severe sepsis describes the occurrence of acute organ dysfunction and 
septic shock, when it is complemented with hypotension (26). Risk factors include chronic 
diseases like COPD or other pulmonary disease, and the use of immunosuppressive agents. 
Severe sepsis may be a result of community-acquired and healthcare-associated infections. The 
clinical presentation may be variable and depends on several factors like the site of infection, the 
causative organism, underlying health status and organ dysfunction. Cardiovascular and 
respiratory symptoms may accompany organ dysfunction. Other organs affected include the 
central nervous system and the kidneys. Criteria for diagnosis include fever (above 38 degrees 
Celsius), hypothermia (temperature below 36 degrees Celsius), elevated heart rate (greater than 
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90 beats per minute), tachypnoea, altered mental status, oedema or positive fluid balance (> 
20ml/kg over 24 hour period) and hyperglycaemia. Inflammatory markers include leucocytosis, 
leukopenia, elevated C-reactive protein, and elevated procalcitonin. Other variables include 
arterial hypertension, acute oliguria, coagulation abnormalities, hyperbilirubinaemia, and 
thrombocytopenia (26).  
Microbiology of Sepsis 
The most common Gram-positive bacteria implicated in sepsis include Staphylococcus aureus 
and Streptococcus pneumoniae. The Gram-negatives include Escherichia coli, Klebsiella species 
and Pseudomonas aeruginosa (26).  
 
Treatment of Sepsis 
Early management includes cardiovascular resuscitation and alleviating the threat of infection. 
Vasopressors, oxygen, intravenous fluids and mechanical ventilation are vital during 
resuscitation. Empiric pharmacotherapy depends on site of infection, hospitalized or home care 
and microbial sensitivity patterns. Antibiotics should be started as early as possible. (26). 
1.3.6. Hospital-Acquired Infection (HAI) 
HAIs are defined as “localized or systemic conditions resulting from an adverse reaction to the 
presence of infectious agents or toxins” (27). HAIs pose a huge burden to costs and hospital stay, 
and are associated with a high (6%) risk of mortality (27). HAIs may occur as a result of 
catheter-related blood stream infections, ventilator-associated pneumonia, surgical site infections 
and catheter-associated urinary tract infections. Signs and symptoms include fever, chills and 
malaise. For catheter-related blood stream infections, the catheter tip is sampled for microbial 
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growth. Ventilator-associated pneumonia requires examination of respiratory secretions. The 
presence of leucocytosis, rhonchi, and a chest radiograph showing infiltrate and compromised 
oxygenation and ventilation are indicative of the condition. Surgical site infections have 
numerous definitions that depend on patient or wound characteristics and positive culture 
findings.  Surgical site infections mainly result from microbes invading the surgical wound at the 
time of surgical procedure. Patients at risk include those with compromised nutritional status, 
those with DM, COPD, other pulmonary disease, renal or hepatic failure, immunosuppression 
and MRSA carriers. Catheter-associated urinary tract infections are common in a hospital setting 
and usually involve organisms that infect the urinary tract. Biofilms may contaminate the 
catheters. Patients at risk also include females, those with renal disease, impaired nutritional 
status and those with infections at sites remote from the primary lesion (27). 
 
Microbiology of HAI 
For catheter-related blood stream infections, causative organisms include Staphylococcus 
epidermis, Staphylococcus aureus, Enterococci, Gram-negative bacilli as well as fungi (Candida 
species). For ventilator-associated pneumonia, the organisms may include Gram-negative bacilli 
such as Pseudomonas aeruginosa, Proteus species, Klebsiella species, Acinetobacter, 
Escherichia coli and Hemophilus influenzae. Staphylococcus aureus and fungi such as Candida 
may also be involved. Surgical site infections are caused by Staphylococcus aureus and some 
Gram-negative organisms. Catheter-associated urinary tract infections are associated with 
Pseudomonas aeruginosa, Escherichia coli, Enterococci, Enterobacter species, Klebsiella 





Treatment of HAI 
General recommendations include hand hygiene, aseptic practice and use of topical disinfectants. 
Catheter-related blood stream infections require removal of the catheter (except in the case of 
Staphylococcus epidermis), and then rapid clearance of bacteraemia. Infections involving 
Staphylococcus epidermis, such as haemodialysis-associated infections, may be treated with 
appropriate antibiotics (27). Antimicrobial therapy should be routinely given over 7 to10 days. 
Patients with complicated infections can receive up to 8 weeks’ of therapy. Ventilator-associated 
pneumonia requires early antibiotic therapy based on cultures and clinical presentation, lung 
abscess drainage or surgical interventions. Catheter-associated urinary tract infections require 
removal of the catheter, and then antibiotic therapy based on culture or the clinical presentation 
(27). 
1.4. Pharmacology 
IC and MEM are both carbapenem antibiotics. These beta-lactam antibiotics are similar to 
penicillins and cephalosporins, but differ in their structure, as shown in Figure 3. 
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Figure 3 - Chemical Structures of Imipenem and Meropenem 
 
The sulphur atom of the thiazolidine ring has been externalized and replaced by a carbon atom 
(28). Carbapenems inhibit bacterial cell wall synthesis. Both IC and MEM exhibit activity 
against a wide range of Gram-positive and Gram-negative aerobic and anaerobic bacteria. They 
are quite stable against beta-lactamases, including extended-spectrum beta-lactamase producers 
(ESBLs). ESBLs are commonly found in Klebsiella pneumonia, Escherichia coli and other 
Enterobacteriaciae (29). Both agents have shown activity against Gram-negative bacteria such 
as Klebsiella pneumoniae, Pseudomonas aeruginosa, Escherichia coli, Stenotrophomous species, 
Acinetobacter baumanii and Enterobacteriaciae. Gram-positive bacteria covered include 
Staphylococcus species, Enterococcus species and Norcadia species (17, 30-32). However, 
carbapenemases may hydrolyse carbapenems, rendering them inactive (29). 
Resistance patterns 
Extensive use of carbapenems may result in the development of resistance, especially among 
Acinetobacter species and Pseudomonas aeruginosa. 
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1.4.1. Imipenem/ cilastatin (IC)  
The first carbapenem became commercially available in 1985 for the treatment of complex 
microbial infections (32). Imipenem, derived from thienamycin, showed significant affinity for 
penicillin binding proteins and was stable against β-lactamases. Imipenem was, however, prone 
to degradation in in the human kidneys by dehydropeptidase 1. Incorporation of an enzyme-
inhibitor such as cilastatin was required to improve activity as well as prevent renal toxicity (29, 
32). IC has been marketed by Merck Sharp and Dome with the trade name Tienam® in Saudi 
Arabia (8). The mode of action of IC allows for activity against Gram-positive and Gram-
negative cocci and bacilli, both aerobes and anaerobes (32).  
 
Dosing of IC  
Both standard dosing of 500mg every six hours (q6h) and 1 gram every eight hours (q8h) results 
in a Minimum Inhibitory Concentration (MIC) of approximately the same time (29). IC is given 
as an intramuscular injection or intravenous infusion of at least 20 minutes. The United states 
FDA has approved the dose of IC from between 250mg q6h to a maximum of 1 gram q8h 
depending on the severity of the infection. The dose should be adjusted in patients  with impaired 
renal function (creatinine ≤ 70 mL/min/1.73 m2) body weight less than 70 kg (33). 
Pharmacokinetics and Pharmacodynamics of IC  
IC given over 20 minutes result in plasma peak levels of 14 -24 mg/L (250mg dose), 21-56 mg/L 
(500mg dose) and 41-83mg/L (1 gram dose) (29). The plasma half-life is approximately 1 hour. 
After 1 hour of dosing the median concentration in the lung tissue is 5.6mg/kg, in the 
endometrial tissue 11.1 mg/kg, in the pleural fluid 22mg/kg, in the cerebrospinal fluid 2.6 mg/L 
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and in the interstitial fluid 16.4mg/L. Efficacy depends on time above the MIC, with the peak 
killing when 40% of the dosing interval has drug concentration higher than MIC (29). 
Safety and tolerability of IC 
The most common reported adverse effects observed in patients were thrombophlebitis/ phlebitis 
(3.1%), nausea (3.1%), vomiting (1.5%) and diarrhoea (1.8%). Seizure rate was found to be 
about 0.4% (29). 
1.4.2. Meropenem (MEM)  
MEM is a broad spectrum carbapenem that was developed and approved by the United States 
FDA later than IC (19, 30). Like IC, it interferes with bacterial cell wall synthesis with activity 
against most Gram-negative and Gram-positive bacteria. The high affinity for penicillin-binding 
proteins results in eventual cell death. MEM is quite stable against ESBLs and unlike IC it is 
much more stable against dehydropeptidase. It has been marketed in Saudi Arabia as Meronem®, 
manufactured by AstraZeneca (8). Meropenem has been reported to be somewhat more active 
against Gram-negative organisms and less active against Gram-positive than IC (19). 
Dosing of MEM  
The standard dose of MEM is from 500mg q8h to 1 gram q8h, given as an IV infusion of over 30 
minutes or a bolus infusion of over 5-10 minutes (34). A maximum dose of 2 gram q8h has been 
used in bacterial meningitis (30). MEM has time-dependent bactericidal activity. This is best 
achieved when the plasma concentration remains above the MIC throughout the dosing interval 
The dose should be adjusted in patients with compromised renal function (creatinine clearance < 
51 mL/min/1.73m2) (34). 
Pharmacokinetics and Pharmacodynamics 
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MEM given at a dose of 500mg achieves peak concentrations of about 23 mg/L, and after 1 gram 
achieves 49 mg/L. Administering 500mg or 1g of MEM as a bolus over 5 minutes achieves peak 
concentrations of 52 and 112 mg/L respectively. The peak concentrations achieved in various 
tissues were as follows : gynaecological tissues (0.3-10.2 µg/g, 500mg), skin (0.5-12.6 µg/g and 
1.3-16.7 µg/g, 500mg and 1 gram), interstitial fluid (3.2 – 8.6 and 20.9 – 37.4 µg/g, 500mg and 1 
gram), intra-abdominal tissue (2.5-3.9 µg/g, 1 gram), peritoneal fluid (7.4-54.6 µg/mL, 1 gram), 
bronchial mucosa (1.3-11.1 µg/g, 1 gram), lung tissue (1.4-8.2 µg/g, 1 gram).  MEM distributes 
widely into tissues and fluids and has an apparent volume of distribution of between 12.5 and 
20.7 litres. The elimination half-life is approximately 1 hour (30).  
Safety and tolerability of MEM  
Reported adverse effects (which occur in <3% of patients) includes nausea, vomiting and 
diarrhoea (2.5%). Seizures occurred in approximately 0.38% of patients (19). 
1.5. Place in Therapy 
The United States FDA has approved the usual IC dosage for mild to severe infections from 
between 500mg to 1 gram every eight to six hours. The approved indications includes 
endocarditis, polymicrobial infections, bacterial septicaemia, gynaecological infections, intra-
abdominal infections (IAI), lower respiratory tract infections (LRTI), urinary tract infections 
(UTI), skin and skin structure infections (SSI), as well as bone and joint infections (33). MEM 
has been FDA-approved for moderate to severe infections, in the treatment of SSI, IAI, bacterial 
meningitis, at a dose of 500mg to 2 gram every eight hour (34). 
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1.5.1. Ministry of National Guard (MONG) Institutional Guidelines  
The Ministry of National Guard (MONG) antimicrobial guidelines (15) restrict- IC to infection 
control practitioners, intensivists and haematology/oncology consultants, while MEM is 
restricted to infection control practitioners only. The following antimicrobial guidelines have 
been recommended at KAH: 
1.5.1.1. Imipenem/ cilastatin 
Acceptable uses: 
a) Treatment of bacterial septicaemia 
b) Treatment of LRTI 
c) Treatment of bone and joint infections 
d) Complicated abdominal infections 
e) Urinary tract infections, if ESBL is suspected 
Acceptable off-label uses 
a) Fever in patients with neutropaenia 
b) Treatment of cystic fibrosis 
c) Infective endocarditis, due to penicillin, aminoglycoside, and vancomycin-
resistant Enterococcus faecalis. 
Unacceptable uses: 
a) Central nervous system infection 
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b) For infections caused by pathogens susceptible to other β-lactams 
c) Infections in patients with end-stage renal disease 
d) Patients with a history of seizures or at risk of seizures 
Dose: 
0.5 – 1 gram given intravenously q6h 
Adverse effects: 
a) Seizures 
b) Cardiovascular adverse effects: palpitations and tachycardia 
c) Local infusion site reaction or induration and thrombophlebitis 
d) Alteration in taste 
e) Thrombocytopenia 
1.5.1.2. Meropenem (15) 
Acceptable uses: 
a) Treatment of bacterial meningitis 
b) Complicated skin and/or soft tissue infections 
c) Complicated abdominal infections 
Acceptable off-label use: 
a) Treatment of healthcare-associated pneumonia 
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Fever in patients with neutropaenia unacceptable uses 
a) Community-acquired pneumonia 
Dose: 
1 gram given intravenously q8h, maximum dose 2 gram q8h 
Adverse Effects: 
a) Inflammation at the site of infusion/ injection 
b) Leukopenia, neutropenia and agranulocytosis 
c) Angioedema, erythema multiforme 




CHAPTER 2: LITERATURE REVIEW 
 
2.1. Introduction 
The principles of a cost-minimization analysis (CMA) require that the alternative medicines (or 
more broadly, the alternative interventions) being compared are considered, a priori, to be 
clinically equivalent. In order to justify the CMA approach used in this study, a literature review 
was first conducted to justify the a priori assumption of clinical equivalence of IC and MEM in 
the types of infections treated and the doses recommended in the KAH guidelines.  
2.2. Literature search approach and methods 
The sources used for the literature search included the Cochrane Library, Medline database, Trip 
database and Google Scholar. The search terms employed included: efficacy, safety, adverse 
reactions, effectiveness, pharmacoeconomic, bacterial infections, skin infections, sepsis, urinary 
tract infections, respiratory tract infections, hospital acquired infections, meropenem and 
imipenem. The study types sought included systematic reviews, meta-analyses, 
pharmacoeconomic evaluations, clinical trials, review articles and retrospective cohort studies 
comparing IC and MEM. All searches were saved in Endnote citation manager. Studies were 
grouped by infection types as listed in the tables below. Key questions sought were:- 
a) Are the results of the study valid? 
b) What are the results? 
c) Will the results help locally? 
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Studies included as justifying the assumption of equivalence were those matching the key search 
terms above, comparing IC with MEM. RCTs were considered the gold standard when 
comparing IC to MEM. Although RCTs were the main focus of the search, other studies like 
systematic reviews, meta-analyses, pharmacoeconomic studies and other review articles were 
reviewed so as to support the assumption of clinical equivalence of IC and MEM, or at least non-
inferiority. Studies were critically appraised for quality and relevance using the “Critical 
appraisal skills programme , United Kingdom” tool (35). Some studies could not be appraised as 
only abstracts were available. Studies that did not demonstrate clinical and safety equivalence 
between IC and MEM or studies which showed superiority of one agent of the other, were also 
described. Details are given in section 2.3.8 together with justification for the value judgments 
made about the relative weight of the evidence retrieved. 
Studies published in any language since the year 1995 were considered, although only those 
provided in English or in English translation could be included. The searches were last updated 










2.3. Literature retrieved 
 
The outcome of the searches conducted is depicted in Figure 4. 
Figure 4- Outcome of literature search 
 
Searches conducted in Google scholar retrieved 413 studies, those in the Cochrane library 
retrieved 72 studies, while the Trip database returned 475 studies and the Medline database 
retrieved 1792 studies. Cochrane library included 1 review, 67 trials, 2 economic evaluations and 
1 ‘other’. The Pubmed search retrieved 50 studies with search terms matching “meropenem 
AND imipenem and safety”, 155 studies matching “meropenem AND imipenem AND efficacy”, 
127 studies matching “meropenem AND imipenem AND adverse”, 1028 studies matching 
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and imipenem AND pharmacoeconomic”. Titles were reviewed so as to eliminate irrelevant 
topics as well as duplicates. Finally a total of 29 comparative studies were retrieved, matching 
the search criteria and applicable to the international context. The abstracts were reviewed to 
assess whether the published articles met the inclusion criteria. No local studies could be found 
which had been published in Saudi Arabia. Of the comparative studies retrieved, 23 showed 
similar efficacy or safety. Some studies could not be reviewed in detail, either due to being in a 
foreign language or where an unclear conclusion was recorded. Tables 1 to 3 summarise the 18 
studies which were assessed as demonstrating the clinical equivalence of IC and MEM. These 
studies were available in the English language (at least as abstracts) and included clear 
conclusions, and met all inclusion criteria. The findings are then described in detail and related to 
the design features of the present study. Table 4 summarises the outcomes recorded in the 6 
studies which did not show clinical equivalence. 
 
2.3.1. Intra-abdominal infections (IAIs) 
Five studies were retrieved; three were RCTs, one meta-analysis and one retrospective cohort 
studies. The study by Attanasio et al. (1) was a cost-effectiveness analysis. Table 1 summarises 
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The studies in the literature review used varied doses of both carbapenems. The present study 
evaluated IC at a dose of 500mg q6h versus MEM 1gm q8h. This dosage has been supported by 
the KAH antimicrobial guidelines (15) as well as the United States Food and Drug 
Administration (FDA) (33, 34). This choice is also supported by a systematic review (36).  
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Zhanel et al. (36) completed a comparative review of IC versus MEM, looking at  
pharmacokinetics, clinical trials and adverse effects. The review was based on a MEDLINE 
search of the published literature from 1975 to 1997. The authors concluded that the use of IC at 
a dose of 500mg q6h and MEM 1 gram q8h in serious infections was supported by the available 
literature. In addition, it was found that IC 2 gram/ day ($98) appears more economical than 
MEM 3 gram/ day ($142/ day). Although this was a systematic review, no details were given in 
regards to the evaluation of the quality or relevance of the studies selected. Only prospective 
randomized trials published in peer reviewed journals were included. However, no direct 
comparisons were double-blinded. The methods of systematic review and statistical analyses 
were not mentioned. None of the trials included showed a statistically significant difference in 
outcomes (clinically or bacteriologically) between the two treatment groups. Both IC and MEM 
shared similar self-limiting adverse effects with notable concern expressed about the possibility 
of seizures in the IC group.  
The study question was relevant to the present study as the infection types considered were 
comparable. These included IAI, respiratory tract infections, septicaemia, bacterial meningitis 
and febrile neutropenia. The present study did not include patients with bacterial meningitis or 
febrile neutropenia.  
The economic analysis was less than ideal, as the authors only considered acquisition costs. At 
the time of the review, the acquisition cost of IC ($98) appears lower than that for MEM ($142) 
at the dose suggested.  
Attanasio et al. conducted a cost-effective analysis of IC (1.5g daily) versus MEM (3g daily) in 
IAIs in multiple hospital settings (20 surgical centres), enrolling 287 patients (1). The University 
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of York’s Centre of Reviews and Dissemination has evaluated this study and found good features 
in terms of validity (accession number 12005000282). Effectiveness data were collected from 
1991 to 1997, while cost data were collected from 1996 to 1997. However, all prices were as for 
1997. The costing was carried out after the effectiveness analysis, which was in the form of a 
multi-centre randomized, parallel clinical trial. Patients included were over 18 years with non-
life-threatening IAI. Patients who needed surgical intervention within 12 hours of traumatic 
bowel perforation or within 24 hours for perforation of gastroduodenal ulcer, or the 
administration of an antimicrobial treatment 48 hours before pre-study evaluation were excluded 
from the study. The direct costs included were those associated with diagnostic procedures, 
medicine acquisitions and administration, management of adverse events and hospitalization, 
based on official price lists for 1997.  Indirect costs were not included. Sensitivity analysis was 
performed on effectiveness estimates and costs. Notably, the doses used varied from those 
applied in the present study at KAH, although the setting was broadly comparable and all 
relevant cost categories were included. The validity of the results were enhanced by the 
sensitivity analysis. The results showed: - IC costs = Lira 106,874 versus MEM = Lira 135,042. 
Attanasio et al. (1) found no statistical difference in clinical (98% IC versus 95% MEM, p = 
0.439),  bacteriological (96% IC, 98% MEM, p = 0.676) response, or in relation to adverse 
events.  
 Badía et al. conducted a meta-analysis of cost-effectiveness data for a range of antibiotics used 
in mild to moderate IAIs (37). Although the full study was only reported in Spanish, the abstract 
was available in English. In this analysis, outcomes were measured in natural units and only 
direct-health care costs were included. Although detailed data could not be obtained from the 
abstract, and the analysis was only based on retrospective data, this meta-analysis did show that 
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IC was clinically as effective (95.2% vs. 96.4%) and less costly than MEM (pesetas. 455 320 
versus pesetas. 483 404).  However, the exact doses used could not be extracted and the target 
population included a broader category of moderate to severe infection than that included in the 
present study.  
Zanetti et al. conducted a multicentre, open-label, randomized trial comparing IC (2 gram/day) 
versus MEM (1.5 gram/day) in IAI, which showed IC to be as clinically effective and well 
tolerated as MEM (38). A clinical cure was achieved in 65/71 (93.8%) treated with IC compared 
with 60/64 (91.6%) treated with MEM.  
Geroulanos et al. reported on a multicentre, open-label, randomized trial comparing IC (3 
gram/day) versus MEM (3 gram/day) in 232 patients with moderate to severe IAI (39). Positive 
clinical responses were achieved in 83/88 (94%) treated with IC, compared with 79/82 (96%) 
treated with MEM. Bacteriological responses were also similar (81% versus 84%). A similar 
incidence of adverse events was observed between the both groups. The study concluded that IC 
was as effective and well tolerated as MEM. 
Beketov et al. reported on a retrospective cohort study, which also showed IC and MEM to have 
similar efficacy, although IC was less costly (40). The comparisons in this study were complex 
though: empiric cefoperazone/sulbactam monotherapy was compared with the IC, MEM and the 
combination of cefepime plus metronidazole. Positive clinical responses in the MEM (87.5%) 
and IC (86.6%) were comparable, and were also not different from those achieved with 
cefepime/metronidazole (85.3%) and cefoperazone/sulbactam (86.8%).  Although few details on 
the costing approach could be extracted, the authors reported that the total cost per 100 patients 
was 3 085 291 roubles for MEM and 2 653 388 roubles for IC.  
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2.3.2. Skin and skin structure Infections (SSIs) 
Three studies were retrieved comparing IC and MEM in SSIs. Two were RCTs and one an open 
label prospective trial. Table 2 summarises the studies which showed clinical equivalence of IC 
and MEM in the treatment of SSI. 
Table 2- Studies showing clinical equivalency in SSI 
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Embil et al. reported on a post hoc subgroup analysis of an international, multicentre, double-
blind randomized trial in hospitalized patients, aged 13 years or older, with SSI (21). The 
subgroup comprised 398 diabetic patients out of a total sample of 1076. . Both IC and MEM 
were given at a dose of 500mg q8h (1.5 gram/day) for a minimum of 3 days. The primary 
efficacy endpoint was clinical outcome at 7 to 14 days after final administration of the study 
agent (test-of-cure visit). The clinical response rate in the subgroup was similar with IC (89.0%) 
IC and MEM (86.6%), and no differences in adverse events were noted.  Although this study 
included younger patients (≥ 13 years), the mean age in the subgroup was 55 years. It was noted 
that a commercial sponsor (AstraZeneca) was acknowledged for their support for the study.  
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Overall, the results were taken to be directly applicable to the patients with SSI seen in the 
present study. Full details of the broader study were also available from a previous publication 
included here as Fabian et al. (41). This prospective, multicentre, international randomized 
double-blind study was one of the largest studies of hospitalized patients with SSI and has been 
frequently cited and considered to be robust. Cure rates were 82.9% (IC) versus 86.2% (MEM). 
Frequencies of ADEs and drug-related ADEs were similar between the 2 groups. This study has 
relevance to the context of the present study in terms of the clinical condition being treated and 
target population. 
Nichols et al. reported on a multicentre, open-label, prospective trial comparing IC 500mg q6h 
(n=193) with MEM 500mg q8h (n=184) in SSI (42). No differences in clinical response (95% IC 
versus 98% MEM) or bacteriological response (IC 91% versus MEM 94%) were noted after an 
average of between 6 to 7 days’ treatment. The authors concluded that MEM was as effective 
and well tolerated as IC.  
2.3.3. Respiratory Tract infections (RTI) 
Table 3 summarises the studies which showed clinical equivalence between IC and MEM in the 
treatment of RTI. 
Three studies were retrieved comparing IC and MEM in respiratory infections. Two were RCT’s 
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No significant difference in 
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bacterial eradication and 
clinical cure rates in the MEM 
group compared to IC. 
Key: RCT = randomized controlled trial; IC = imipenem/ cilastatin; MEM = meropenem; ADE = adverse drug 
events; 95% CI = 95% confidence interval; N/A = not available 
All three studies in patients with lower respiratory tract infections were conducted in Chinese 
subjects, and could be obtained in abstract form only. As no details of the target population were 
provided, their applicability to the local context of the present study could not be established.  
Xiao-Ju et al. reported on a randomized controlled trial of IC (1 gram q12h or q8h) versus MEM 
(500mg q12h or q8h (43). Cure rates were 65.38% (IC) versus 73.08% (MEM); effective 
responded patients 92.31% (IC) versus 96.15% (MEM); bacterial eradication rates 96.15% (IC) 
versus 100% (MEM); adverse reactions 7.69% (IC) versus 11.54% (MEM). This was small 
study, with only 52 participants, but did show equivalence in terms of clinical response and 
bacterial eradication rates. 
Song et al. conducted an RCT in 60 patients with respiratory tract infections (44). The cure rate, 
effective rate and bacterial clearance rate for MEM were 80.0%, 93.3%, 92.3%, respectively and 
IC were 76.7%, 90.0% and 91.3%, respectively. Rate of adverse reactions for both was 3.3%. 
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Similar cure rates and bacterial clearance rates were shown for IC and MEM. The authors also 
concluded that safety profiles were similar.  
Xiao H et al. reported on a meta-analysis of 9 RCTs, retrieved by searching the PubMed database 
and China National Knowledge Infrastructure database between 1983 and 2009 (45). These 
authors used a dated method of assessing study quality (the Jadad scale). Heterogeneity was 
examined by Revman5.0 and Stata 10.0. Publication bias was assessed using Egger’s test and 
Begg’s test. MEM showed higher bacterial eradication rate compared with IC in moderate or 
severe pulmonary infection (OR: 1.62, 95% CI: 1.03-2.53). Clinical cure rate displayed a 
borderline statistical significance (OR: 1.39, 95% CI: 1.00-1.94). Clinical efficacy rate and 
incidence of adverse reactions did not show any significant difference between the two drugs 
(P=0.05). The authors concluded that there was no significant difference in clinical efficacy and 
adverse reactions with slightly higher bacterial eradication and clinical cure rates in the MEM 
group compared to IC. 
2.3.4. Urinary Tract Infections (UTIs) 
Only one comparative study of IC and MEM in UTIs was retrieved. Cox et al. conducted a 
prospective, stratified, randomized, multicentre open-label, parallel group trial comparing IC 
500mg q6h (n=119) and MEM 500mg q6h (n=116) in adult (≥ 18 years old), hospitalized 
patients with complicated UTIs requiring intravenous antibiotics (25). The focus of infection in 
this study was defined well. The sample size was large, but neither participants nor study staff 
were blinded. Clinical response in both the IC and MEM groups was 99%. A positive 
bacteriological response was achieved by 81% in the in IC group and 90% in the MEM group. 
The authors concluded that MEM is a safe and effective alternative to IC. The inclusion and 
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exclusion criteria applied in this study were similar to those applied in the present study. Clinical 
response was evaluated at the end of treatment and follow up done after more than 21 days.  
2.3.5. Sepsis 
Only the abstract for one small open label, prospective RCT (n=53) comparing IC (2 gram/day) 
versus MEM (2 gram/day) in hospitalized Chinese septic patients  could be found, reported by 
Kuo et al. (46). . The study reported no difference in clinical (76% IC versus 84% MEM) and 
bacteriological (75% IC versus 80% MEM) outcomes. The authors concluded that MEM was as 
effective and well tolerated as IC in bacteraemia patients.    
2.3.6. Bacterial Infections 
Two RCTs was retrieved comparing IC with MEM in bacterial infections. These were defined as 
LRTIs, UTIs, SSIs as well as IAIs and Sepsis. 
Three additional studies were retrieved which reported on outcomes in a range of bacterial 
infections. Hou et al. reported on a multicentre, open-label, RCT evaluating the efficacy and 
safety of IC versus MEM in 182 hospitalized Chinese patients with LRTIs, UTIs and other 
infections including SSI (47). . Patients aged ≥ 16 years old received 500mg – 1 gram of either 
antibiotic q12h for 7-14 days. The study excluded patients with severe cardiac, hepatic, renal or 
hematopoietic abnormalities. Withdrawal criteria were established for in cases where pathogen 
was resistant, where a negative culture was obtained within 72 hours, and when serious adverse 
events occurred. The study followed Good Clinical Practice guidelines and was notable for a low 
withdrawal rate (20 patients). Cure rates were 57% in the IC group and 66% in the MEM group 
(P=0.298). Overall efficacy rates were 87% in the IC group and 90% in the MEM group 
(P=0.595).  For LRTI the clinical efficacy rates were 77% and 86% for IC and MEM 
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respectively, 100% for UTI’s and 89% for IC and 85% for MEM (P=0.219). The difference 
between the groups was not statistically different. Adverse drug events were observed in 8.6% of 
IC patients compared to 9.7% in MEM group. (P=0.812). The results showed no statistical 
difference between the 2 groups in terms of efficacy and safety. Although the dosing used 
differed from that in the present study, the results were considered to be applicable. The target 
population was similar (LRTI, UTIs and SSI) and could be generalized to the setting of the 
present study.  
Vewaest et al. conducted a multicentre, open-label, randomized, parallel-group trial evaluating 
IC and MEM (1 gram/day) in 212 intensive care patients aged ≥ 18 years with bacterial 
infections involving LRTI, IAI and sepsis (17). . Overall efficacy rates were 68.1% in the IC 
group versus 77.0% in the MEM group (P=0.185).Both drugs had similar response rates in terms 
of LRTIs and sepsis, however MEM performed better in IAI. This was a well-conducted 
randomized trial, which should have increased the validity of the findings. However the method 
of randomization was not mentioned. There was no blinding in this study, which could have 
introduced bias. The patient population was similar to that targeted in the present study in terms 
of baseline demographics as well as the primary infections. Clinical cure was well defined using 
APACHE II scoring system and follow up was 2-4 weeks.  
 
Colardyn et al. conducted a randomized, prospective multicentre study for the treatment of 
serious infections in 204 adult patients (≥18years) (48). Both IC and MEM were given at a dose 
of 1 gram q8h as monotherapy. Infections included IAI, SSI, LRTI, UTI, bacteraemia and a case 
of meningitis. Clinical response was seen in 77% of cases with IC and 76% of cases with MEM. 
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Bacteriological eradication rated were also not statistically different and adverse events were 
considered to be similar for both groups (IC=12 and MEM =9). This study included 1 case of 
meningitis, which the present study excluded. The study further excluded patients with central 
nervous system disease, osteomyelitis, endocarditis or cystic fibrosis. Since there was no 
blinding, the possibility of bias could not be excluded. Clinical definitions were not as rigid as 
might be expected.  Follow up was variable (2-4 weeks or 4-6 weeks). Adverse events were not 
clearly defined and the study noted only observed occurrences.  However, the study population 
was similar in terms of baseline characteristics as well as including patients from both intensive 
care and general wards.  
2.3.7. Studies which showed differences in outcomes between IC and MEM 
Edwards et al. (2) performed a cost-utility analysis simulating the ICU processes using costs and 
QALY, in a United Kingdom hospital setting (ICU). This economic analysis found MEM to be 
cost-effective when compared to IC. It was not clear if the authors’ performed a systematic 
review. The viewpoint of the NHS was used in the study and the costs were not detailed. Direct 
costs were apparently used, including hospital stay and resource consumption. Some data were 
obtained from expert opinion. A published systematic review and clinical trials were used. The 
study used utility values appropriate for a United Kingdom setting, which might not be easily 
translated to other settings. IC costs were £15,585.30 compared with £14,938.06 for MEM. The 
QALYs gained were 7.413 QALY for IC versus 7.495 QALY for MEM. Clinical response (7.4% 
IC versus 9.5% MEM) and bacteriological response (80.4% IC versus 84.6% MEM) was 
recorded. The study uses transitional probabilities deduced from a systematic review, using a 
Markov model approach and concluding superiority of MEM.  The study concluded that MEM is 
significantly more effective and less costly than IC. 
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Table 4 - Studies which showed differences in clinical outcomes 
Citation Study 
Design 
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The costing data used, in particular the resource consumption, was not clear. Edwards et al. (49) 
also performed a systematic review supported by AstraZeneca, the manufacturer of MEM. 
Clinical response was reported to be statistically higher for MEM than IC (RR 1.04, 95% CI: 
1.01, 1.06). Bacteriologic response was also statistically higher with MEM than with IC (RR 
1.05, 95% CI 1.01, 1.08). No difference in mortality (RR 0.98, 95% CI: 0.71, 1.35) was reported. 
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Fewer adverse effects were observed in the MEM group compared to the IC group (RR 0.87, 
95% CI: 0.77, 0.97). Only the abstract was available and the level of significance could not be 
ascertained. The authors concluded that MEM was clinically and bacteriologically superior to IC 
and had fewer side effects. These conclusions were not in agreement with several studies 
outlined above.  In addition the systematic review by Hoffman et al. (54) did not agree with the 
conclusions that MEM is safer than IC. Ten studies did not agree with this study, which showed 
similar tolerability as, listed in Table 6. The applicability of pharmacoeconomic evaluation to the 
local setting was questionable. However the systematic review was the only study of good 
quality which found superiority in efficacy and safety, favouring MEM. Overall, the balance of 
evidence still indicates the clinical equivalence of IC and MEM as summarized in Table 6. 
Novelli et al. (50) suggested that IC showed more favourable outcomes when compared to 
MEM. The study endpoints in this case were pharmacokinetic parameters. The mean peak serum 
concentration was higher for IC than for MEM (90.1 ± 50.9 vs 46.6 ± 14.6 mg/L, p < 0.01); the 
area under the serum concentration-time curve was also higher for IC (216.5 ± 86.3 vs 99.5 ± 
23.9 mg/L, p < 0.01), while the mean volume of distribution and mean total clearance were 
significantly higher for MEM than for IC (25 ± 4.1 vs 17.4 ± 4.5L, p < 0.01 and 191 ± 52.2 vs 
116.4 ± 42.3 mL/min, p < 0.01, respectively).Clinical, bacteriological or safety endpoints were 
not considered and as such, conclusions of efficacy and safety could not be deduced from this 
pharmacokinetic study.  
Kohno et al. (51) reviewed phase II and phase III trials of the four available carbapenems. The 
authors suggested that MEM showed superiority in terms of clinical efficacy, but referenced 
other double-blind studies that showed no difference between IC and other carbapenems. 
Clinical efficacy rates reported were 79% for IC and 100% for MEM.  
43 
 
Maggioni et al. (52) conducted a multicenter RCT evaluating clinical, bacteriological and safety 
outcomes in obstetric and gynaecological infections, the authors reported a  better clinical 
response and side effect profile in the MEM group. Clinical cure for IC was 84.6% and for MEM 
was 100% (p = 0.026). IC showed more side effects (15.1% versus 11.5%, level of significance 
not reported). Patients with obstetric and gynaecological infections were not included in this 
study and these data were thus excluded from the evaluation.  
Shah et al. (53) found MEM to be better tolerated than IC, however clinical efficacy was found 
to be similar. Cure rates were 60% with IC and 58% with MEM. Nausea and vomiting occurred 
in 7/33 patients on IC versus 2/33 on MEM. This study was not in agreement with the ten studies 
that showed no difference in safety outcomes as listed in Table 6. Nevertheless it did conclude 
that there was no difference in clinical efficacy between IC and MEM. 
2.3.8. Adverse Drug Events (ADEs) 
The safety of IC versus MEM, with particular focus on the risk of seizures, was the subject of a 
systematic review  reported by Hoffman et al. (54). Studies were retrieved from MEDLINE for 
the period 1966 to 2007, and included many of the studies described above. Four RCT’s showed 
similar safety outcomes. The largest trial by Verwaest et al. (17) reported IC = 3/105 (2.9%) and 
MEM = 4/107 (3.7%) drug-related seizure in patients with CNS disease. In the second trial by 
Colardyn et al. (48) , patients with CNS disease were excluded with adverse effects in 12 patients 
(12%) in the IC group and 9 (10%) in the MEM group. The third trial by Garau et al. (55) 
excluded patients with CNS disease or previous history of seizure. Drug-related adverse events 
occurred in 11 (15%) of IC patients and 13 (17%) of MEM group. Two seizures were found in 
each group. Observations of 1754 patients by Calandra et al. (56) treated with IC 2gram/ day in 
phase III clinical trial were reviewed to determine the risk of seizures . The results reported 52 
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patients (3%) had seizures and 16 (0.9%) were classified to be possibly, probably, or definitely 
IC related seizures. Of these patients, the majority had a background of seizure-risk. In a review 
of almost 5000 patients on MEM (57); overall incidence of seizures were reported in 22 (0.46%) 
of patients. The overall seizures considered to be related to MEM were 4 (0.08%). In 278 
patients treated for meningitis 20 (7.2%) experienced seizures with MEM compared to 26 (9.8%) 
patients treated with cephalosporins. Similar findings were found in several other studies. The 
author found that elderly patients, patients with low body weight, at risk of CNS disease, history 
of seizure and renal dysfunction appears to be associated with increased risk of drug related 
seizure. The authors highlighted one paediatric study (3) which is often cited as the reason for IC 
associated seizures. Seizure rates were nonetheless shown to be similar when either IC or MEM 
were used. 
2.3.9 Pharmacoeconomic review 
Four studies Table 5 showed that IC is less costly than MEM. Only the study by Attanasio et al. 
(1) used well-described pharmacoeconomic principles, as described in section 2.3.1. Badia et al. 
(37) measured direct health cost using a meta-analysis approach to cost effectiveness data.  
However, the details of this study could not be obtained as it was in a foreign language. The 
study by Zhanel et al. (36) was less than ideal as it only included acquisition costs, while in 
Beketov et al. (40) the costing approach was not sufficiently detailed to allow interpretation. The 
study by Edwards et al. (2), supported by AstraZeneca,used well-described pharmacoeconomic 
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2.4. Summary of literature review 
A fundamental prerequisite for performing a cost minimization analysis in this study was 
establishing clinical equivalence between IC and MEM, or at least non-inferiority in both 
directions. The evidence sought were comparative studies focusing on IAI, SSI, LRTI, UTI, 
sepsis, bacteriological outcomes, and safety. In addition, pharmacoeconomic studies were being 
sought. The literature review focused on establishing that IC is clinically equivalent to MEM in 
clinical, bacteriological and safety outcomes. 
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In terms of a hierarchy of evidence, the search found 2 meta-analyses, 12 RCTs, 1 prospective 
cohort and a retrospective cohort study that supported the position of clinical equivalence 
between IC and MEM. The six studies that did not show clinical equivalence were a 
pharmacoeconomic review, two systematic reviews and 3 RCTs. There were 4 
pharmacoeconomic evaluations showing IC to be less costly than MEM. Of the most robust 
evidence were: a meta-analysis by Xiao H et al. (45), which was well-detailed. The second meta-
analysis could only be retrieved as an abstract, as the original was in the Spanish language. 
Among the RCTs, 1 was blinded (41), while 11 were open-label trials. Two systematic reviews 
were selected. One pharmacoeconomic (1) review was considered to be of good validity. 
The key findings of this appraisal provided convincing evidence of the clinical equivalence of IC 
and MEM. These findings answer the search questions in the following way: 
a) IC is clinical equivalent to MEM in IAI, SSI, LRTI, UTI and sepsis 
b) IC has an equivalent bacteriological response to MEM 
c) IC is as safe as MEM 
d) IC is less costly than MEM 







The evidence for clinical equivalence was evaluated as follows: 
Table 6 - Summary of critical appraisal 
 Critical appraisal findings Supported by 
1 IC clinically equivalent to MEM 
in patients with IAI 
No difference in clinical efficacy supported by 
studies (1, 36-40, 48). 
2 IC clinically equivalent to MEM 
in SSI 
No difference in clinical efficacy supported by 
studies (21, 41, 42, 48). 
3 IC clinically equivalent to MEM 
in LRTI 
No difference in clinical efficacy supported by 
studies (17, 43-45, 47, 48). 
4 IC clinically equivalent to MEM 
in UTI 
No difference in clinical efficacy supported by 
studies (25, 47, 48). 
5 IC clinically equivalent to MEM 
in Sepsis 
No difference in clinical efficacy supported by 
studies (17, 46). 
6 IC bacteriologically equivalent to 
MEM 
No difference in bacteriological outcomes supported 
by studies (1, 25, 39, 44, 46). 
7 IC as safe as MEM No difference in adverse drug events supported by 
studies (1, 17, 21, 25, 38, 39, 41, 42, 45-48, 54). 
8 IC less costly than MEM IC less costly than MEM supported by studies (1, 
36, 37, 40) .  
9 IC 500mg q6h and MEM 1gram 
q8h 
This dosage supported by Zhanel et al. (36), United 
states FDA (33, 34) and our hospital Antimicrobial 
guidelines (15). 
Key: IAI = intra-abdominal infection, SSI = skin and skin structure infection, LRTI = lower respiratory tract 










CHAPTER 3: METHODS 
 
3.1. Introduction 
This chapter sets out to describe the research methods employed, the type of research, study 
design, study population, inclusion and exclusion criteria, data collection methods, definitions 
and pharmacoeconomic approach. 
3.2. Type of Research 
This study was a retrospective, single-centre cohort employing cost minimization principles. The 
CMA assumes that consequences are equivalent while considering the least expensive alternative 
(13, 58). As outlined in the literature review, IC is considered to be clinically equivalent to MEM 
in terms of safety and efficacy. An institutional review indicates that an interchange program of 
IC with MEM could save the institution more than SAR 2 million. As the initial review only 
included acquisition costs of the drugs, a costing analysis of this nature was considered to 
include resource costs relevant to the primary infection. 
3.3. Study Design 
A cost minimization analysis of IC versus MEM in moderate to severe infections was conducted 
at the King Abdulaziz National Guard Hospital, Al-Ahsa (a 300 bed tertiary care centre). 
Between January 2012 and December 2012, all patients receiving IC 500mg every six hours and 
MEM 1 gram every eight hours for moderate to severe infection were included in the study.  
The perspective of the economic evaluation was that of the Ministry of National Guard in Saudi 
Arabia that provides health-care to eligible dependents. The eligible dependents include 
employees of the National Guard, their families, staff and their families. The majority of the 
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patients at the hospital receive free medical treatment while approximately 20 beds are reserved 
for cash paying private patients. Only direct costs were included in the study, based on the 
October 2013 hospital business centre pricing. Medicine acquisition prices were obtained from 
the October 2013 Saudi Food and Drug Administration (SFDA) Human Drug pricing list (8). 
Direct costs included medications, supplies, laboratory tests, health-care professionals’ time and 
hospitalization costs(13).  All costs are expressed as Saudi Riyals (SAR).  
3.3. Target Population 
Patients on IC or MEM with moderate to severe infection, eligible to receive treatment at our 
institution.  
3.4. Study Population 
3.4.1. Inclusion criteria: 
a) Adult patients (≥ 18 years old).  
b) Patients diagnosed with moderate to severe infection, including SSI, sepsis, IAI, 
respiratory tract infections, UTI and HAI who were prescribed IC 500mg every six hours 
intravenously (2 gram per day). 
c) Patients diagnosed with moderate to severe infection, including SSI, sepsis, IAI, 
respiratory tract infections, UTI and HAI who were prescribed MEM 1 gram every eight 
hours intravenously (3 gram per day).  
3.4.2. Exclusion Criteria: 
Patients excluded from the study were: 
a) those that were pregnant 
b) those with known or suspected meningitis 
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c) those diagnosed with microorganisms resistant to IC or MEM  
d) patients with a documented hypersensitivity or prior contraindication to IC or MEM. 
3.5. Sampling 
The study set out to capture a year’s sample including 100 patient files with 50 patients in each 
arm. The study period included 1 January 2012 until 31 December 2012.  
3.6. Data Collection 
Data were extracted from the electronic and paper medical records maintained by the King 
Abdulaziz National Guard Hospital information system. Records were searched from 1 January 
2012 until 31 December 2012. The search included any patient either on IC or MEM during the 
study period. The search results were exported to Microsoft® Excel. The search fields included 
patients’ medical record number, name, date of birth, study drug (either IC or MEM), dosage, 
admission date and number of doses given. Patients were matched as per the inclusion and 
exclusion criteria. Data on patients’ gender, age, weight, diagnosis, medical history, laboratory 
test (including renal function and haematological status), recorded comorbid illnesses and 
previous medicines allergies, prescribed antifungals or antibiotics and microbiological tests were 
extracted from the hospital’s electronic medical record, with the assistance of the hospital 
information management department. Information about consultant and physician visits was 
extracted from the paper based physician notes, as were clarifications of the recorded diagnosis 






The following variables were captured in relation to each patient and his/her hospital stay: 





2. Diagnosis and primary infection 
3. Doses administered of IC or MEM  
4. Doses administered of concomitant antibiotics or antifungals  
5. Microbiology and source of infection. 
6. Sensitivity or resistance patterns of identified micro-organisms 
7. Number and type of laboratory procedures used to test for sensitivity patterns, monitoring of 
primary infection failure or superinfections, source of infection 
8. Laboratory tests conducted: 
8.1. full blood count 
8.2. liver function tests 
8.3. renal function  
8.4. coagulation studies 
9. Vital signs including temperature 
10. Recorded adverse drug events 
11. Physician consultations  
12. Nursing visits 
13. Pharmacist processing and preparation time 
14. Pharmacy aide delivery time 
15. Daily consumables used in the administration of medicines 





From the variables listed above, the following outcomes were documented: 
a) adverse drug events (ADE) associated with either IC or MEM, using previously 
published criteria (29) 
b) length of hospitalization 
c) length of antibiotic stay (LOAS); defined as the number of hospital days during which the 
patient was being treated for the diagnosed infection, including any treatment associated 
with treatment failure or related adverse effects 
d) resource consumption, limited to direct medical costs of managing the primary infection 
based on the institutional perspective. 
 
3.8. Definitions  
3.8.1 Definitions of moderate to severe infections 
The diagnosis of moderate to severe infection was based on the treating physician’s documented 
clinical decision, using the criteria below: 
a) Skin and skin structure infections (SSI) –  
restricted to signs and symptoms associated with cellulitis, infected wounds, infected skin 
ulcers, and abscesses (20, 48).  
b) Sepsis - : 
defined as a fever with temperature above 38.3 degrees Celsius, with chills, leucocytosis, 
hyperventilation, hypothermia, skin lesions, septic embolism, change in mental status, 
hypotension, disseminated intravascular coagulation, or organ failure (17, 26).  
c) Intra-abdominal Infections (IAI) - :  
evidence of abscess, or peritonitis originating from the stomach, duodenum, biliary tract, 
pancreas, appendix, small intestine and colon (16, 17, 48).  
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d) Lower respiratory tract infections (LRTIs) - :  
evidence of pulmonary infiltration thought to be due to infection on the chest X-ray and 
at least two of the following criteria: purulent sputum (<10 squamous epithelial cells, > 
25 white blood cell counts (WBCs) and a pathogen should be cultured), fever and 
leucocytosis (16, 17).  
Urinary Tract Infection (UTI) - :  
evidence of dysuria, frequency, urgency, suprapubic pain, and/or haematuria, fever 
greater than 38 degrees Celsius, urinalysis, history of previous UTI, urine culture showed 
positive bacteriological growth (24, 48).  
Hospital Acquired Infection (HAI) -:  
defined as late onset infection (> 72 hours after admission), post-surgical infection, or 
early onset (and community acquired, with onset considered as early onset (< 72 hours 
after admission) (27).   
3.8.2 Adverse drug events (ADE):  
Adverse drug events (ADEs) associated with IC or MEM were identified based on physician 
documentation and the records extracted from the hospital information system. The following 
circumstances were considered to be indicative of an adverse drug event associated with IC or 
MEM: 
1. seizure diagnosed by the physician, within twenty four hours after either IC or MEM was 
administered.  
2. anti-epileptic medication (phenytoin, carbamazepine, phenobarbital or levetiracetam) 
prescribed within twenty four hours of initiating IC or MEM 
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3. skin reactions (rash, pruritus, urticaria, erythema multiforma, and Stevens-Johnson 
syndrome) 
4. gastrointestinal disturbance such as antibiotic-associated diarrhoea, nausea or vomiting. 
A Clostridium difficle culture was considered as antibiotic-associated diarrhoea if it was 
confirmed immediately after initiation of the study drug. This was further verified if any 
medication was started to treat the infection like oral vancomycin.  
5. changes in liver function tests of more than 3 times the upper normal limit (aspartate 
aminotransferase > 100 units/ L or alanine aminotransferase > 100 units/L), and 3 times 
the upper normal limit of total bilirubin (>60µmol/L) (54, 59)  
6. changes in renal function (creatinine clearance < 50ml/min) 
3.9. Costing 
Pricing was obtained from the financial sector of the hospital’s business centre. The national 
drug pricing was obtained from SFDA. The most recent pricing available at the time was taken 
in October 2013 from the business centre as well as the SFDA Human Drug List 
(http://www.sfda.gov.sa). Direct medical costs include medications, laboratory costs, health care 
provider costs, hospitalization costs, consumables and administration costs. Direct non-medical 
costs (transportation and food) were not included in the study. Indirect medical costs (lost 
income) and intangible costs (pain and suffering) were excluded as incompatible with the 
perspective of the present study. The perspective was that of the payer, a government institute. 
Costs associated with support personnel such as maintenance, housekeeping, patient escort and 
administration were assumed to be fixed and were not included in the study. Laboratory data 
unrelated to the primary infection or super infections were not considered in the study. 
Investigators’ and data collectors’ fees were excluded. Discounting was not considered as the 
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study period was for a year. Pricing was in Saudi riyals (SARs). One SAR has been fixed at 
approximately 0.27 United States dollars (USD) for the last 10 years. 
Drugs were priced on the generic brands available in the institution. The Business Center pricing 
as at October 2013 was as shown in Tables 7 to 12.  
Table 7 - Cost of hospital stay (daily and other charges) 
  Cost of Hospital Stay 
Type of ward or service Cost 
(SAR) 
Critical Care unit/ day 1500 
High Stay ward/ day 900 
General ward/ day 500 
Consumables ICU/ day 250 
Consumables General Ward/ day 50 
Administration set + 50ml normal saline or equivalent for intravenous infusion/ 
dose 
11 
   Key: ICU = Intensive care unit 
 
Table 8 - Personnel costs 
Personnel Costs 
Type of Service Cost (SAR) 
Intensive care consult/ visit 1000 
General ward consult/ visit 200 
Physician consult/ visit 200 
ICU Nurse/ Day 300 
General ward Nurse/ Day 100 
Pharmacist / minute 1.2 
Pharmacy Aide/ minute 0.4 







Table 9 - Laboratory costs 
Laboratory Cost (SAR) 
CBC 80 
Basic Screen 240 
LFT 200 
PT/PTT/INR 80 
Vancomycin level 180 
Key: SAR = Saudi riyal, CBC = complete blood count; LFT = liver function test; 
 PT = prothrombin time; PTT = partial thromboplastin time 
 
Basic Screen includes blood urea nitrogen, electrolytes (sodium, potassium and chloride), blood 
glucose and serum creatinine. LFTs include alanine transaminase, aspartate aminotransferase, 
alkaline phosphatase, total protein and bilirubin. 
Table 10 - Cost per laboratory culture 








Nare (MRSA) 300 
Rectal 150 
Body Fluid 170 
TB 600 
C.difficle 150 
Faecal/ Stool 150 
Cather Tip 150 
Respiratory 190 
Fungal 180 





Table 11 - Antifungal costs per unit 
Antifungal Cost (SAR) 
Amphotericin IV 444.33 
Caspofungin 50mg IV 2548.45 
Fluconazole IV 77.1 
Fluconazole 50mg IV 8.36 
Fluconazole 150mg IV 25.2 
Voriconazole 200mg IV 587.75 
All costs are expressed as unit costs (cost per vial) 
 
Table 12 - The SFDA Drug Pricing October 2013 (based on the available generic brand) 
Drug cost (SAR) Drug cost (SAR) 
Amoxicillin 250mg PO 0.91 Ethambutol 400mg PO 0.86 
Amoxicillin/ clav 600mg IV 10.18 Gentamicin 80mg IV 13.54 
Amoxicillin/ clav 625mg PO 3.30 IC 500mg/ 500mg IV 70.40 
Azithromycin 250mg PO 12.24 INH 100mg PO 0.07 
Azithromycin 500mg IV 60.25 Linezolid 600mg IV 301.58 
Cefazolin 1gram IV 8.30 Linezolid PO 250.00 
Cefepime 1gram IV 40.45 MEM 1gram IV 151.26 
Ceftazidime 1 gram IV 57.30 Metronidazole 500mg IV 8.15 
Ceftazidime 2 gram IV 114.60 Metronidazole 500mg PO 0.32 
Ceftriaxone 1gram IV 51.75 Moxifloxacin 400mg IV 155.05 
Cefuroxime 500mg PO 8.18 Moxifloxacin 400mg PO 16.40 
Cefuroxime 750mg IV 15.00 Nitrofurantoin 100mg PO 0.78 
Cephalexin 500mg PO 2.00 Norfloxacin 400mg PO 1.74 
Ciprofloxacin 200mg IV 63.45 Piperacillin Tazobactam IV 101.80 
Ciprofloxacin 250mgPO 2.28 Pyrazinamide 500mg PO 0.60 
Clarithromycin 250mg PO 4.31 Rifampicin 300mg PO 2.70 
Clindamycin 150mg PO 1.29 Streptomycin IV 4.00 
Clindamycin 600mg IV 21.10 Tigecycline IV 215.13 
Cloxacillin 500mg IV 17.28 Trimeth/ sulfamethox DS PO 2.33 
Colistin IV 35.05 Trimeth/ sulfamethoxaz IV 10.83 
Erythromycin 250mg PO 0.55 Trimeth/sulfamethoxaz PO 1.18 
Erythromycin IV 500mg 22.90 Vancomycin 1gram IV 64.35 
Key: SAR = Saudi riyal, PO = oral; IV = intravenous, IC = imipenem/ cilastatin; MEM = meropenem 
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3.10. Pharmacoeconomic analysis 
3.10.1 Cost minimization analysis  
As this is a cost-minimization analysis, the assumption of equivalent efficacy was demonstrated 
by the literature retrieved and cited and not the outcomes of patients treated, whose cost data are 
being sought in this study. Evidence of the outcomes in each case was documented by the 
attending physician in the clinical notes. Clinical success was therefore dependent on the source 
of infection and defined by clinical improvement in signs and symptoms that would warrant 
resolution of fever or clinical signs of infection, discontinuation of antibiotics or discharge from 
the hospital without re-admission within 10 days or eradication of baseline positive 
microbiological pathogens. 
3.10.2 Perspective and timescale 
The economic analysis was based on our institutional perspective. The study period began at the 
point the primary infection was diagnosed.  The LOAS was used to determine the time period of 
the costing analysis.  
Costing data relating to the primary infection was included. This included:  
1. total amount of study agent (IC or MEM) per day,  
2. ancillary antibiotics used for the study period,  
3. any non-study medicines related to super infections or treatment failure 
4. any failed antibiotics started prior to the study drug. These were medicines that were 
discontinued as they proved to be unsuccessful in treatment. 
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5. standard laboratory tests such as microbiological culture studies, vancomycin levels, 
complete blood count (CBC), basic screen and coagulation profile  
6. costs related to adverse events 
7. costs related to all, health care worker visits 
8.  medication delivery costs. 
 Health care worker costs included daily critical care units (CCU) consultation, CCU nursing 
costs per day, general ward consultation, physician consultation, general ward nursing costs and 
pharmacy processing and preparation time. Included in the study was the costs relating to 
hospital stay in CCU, step-down unit and general ward. Pharmacy aide delivery time was 
considered. Daily consumable charges were based on the institutional charges and included in 
the costs. 
Support personnel such as maintenance, housekeeping, patient escort and administration costs 
were assumed to be fixed and were not included in the study. Laboratory data unrelated to the 
primary infection or super infections were not considered in the study. Investigators’ and data 
collectors’ fees were excluded. Discounting was not considered as the study period was for a 
single year. 
3.10.3 Sensitivity Analysis 
One-way sensitivity analysis was performed, in Microsoft® Excel 2010, by increasing and 
decreasing each parameter by 20%, while observing the impact on the results. The change in a 
single parameter assisted in identifying those factors that had the greatest impact on the 
conclusions of the study (total costs). The higher number of CCU days in the IC group was 
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expected to influence the overall average daily costs. One-way sensitivity analysis was carried 
out on the following: 
a) Mean daily CCU day costs 
b) Mean daily step-down costs 
c) Mean daily general ward (GW) costs 
d) Mean daily vial costs 
e) Mean daily administration sets costs 
f) Mean daily laboratory costs 
g) Mean daily laboratory culture costs 
h) Mean daily CCU consultation costs (specialist fees) 
i) Mean daily GW consultation costs (specialist fees) 
j) Mean daily physician costs 
k) Mean daily CCU nurse costs (critical care nurse fees) 
l) Mean daily GW nurse costs 
m) Mean daily Pharmacist costs (processing, preparation and dispensing) 
n) Mean daily Pharmacy aide costs (delivery costs) 
o) Mean daily ADE costs 
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A threshold analysis was performed, in Microsoft® Excel using ‘what-if-analysis’. It was 
performed on those parameters thought to impact on the conclusions of the study. A threshold 
analysis was performed on: 
a) CCU days 
b) step-down days 
c) general ward days 
d) ADEs 
e) vial costs 
f) administration sets 
g) pharmacists costs 
Hypothetical values were run through each parameter to find the threshold value at which the 
conclusion changed. The parameter in questions was varied, while the other parameters were 
kept at their original value (base value). The input and output results were then displayed 
graphically to assess the threshold value at which the results (mean total costs) of the study 
would change significantly. The objective was to find the threshold value at which IC became 
less costly than MEM. It was assumed that total costs should be less than SAR 3795.00 if the 
conclusions of the study would change. This value was obtained using the independent sample 
T-test so as to obtain a p-value less than 0.05. 
3.11. Statistical analyses 
Statistical analysis was done in coordination with the King Abdullah Medical Research Center 
using SPSS version 21. An independent sample T-test was used to test the difference between the 
means as well as the level of significance. The test compares the mean scores of the two 
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independent groups. The independent T-test assumes that the dependent variables are normally 
distributed with the two comparators having equal variance on the dependent variable.  
Independent sample T-test was performed on the following parameters: 
a) Baseline demographics (age, weight and height) 
b) Hospital days (CCU days, step-down days and GW days) 
c) Personnel visits (consultant, physician, nursing, pharmacist and aide visits) 
d) Administration sets 
e) Doses administered of IC or MEM 
f) Doses of concomitant antibiotics or antifungals 
g) LOAS 
h) Peak temperature recorded 
i) WBC 
j) Costs related to hospital stay (CCU, step-down and GW) 
k) Costs related to laboratory tests and cultures 
l) Resource (personnel costs) 
m) Cost of ADEs 
Chi square tests of independence were performed on categorical variables on the following 
parameters: 
a) Gender 
b) Clinical success 
c) Renal function  





3.12. Reliability and Validity of Data Source 
The reliability and validity of the data sources was dependent on the accuracy and completeness 
of information recorded. As the hospital is accredited by the Joint Commissions International, 
medical records were relatively complete. Pricing used was the most recent (October 2013), 
supplied by the business centre. Data were captured in the relevant data collection sheet and was 
subsequently verified by a second pharmacist (Analyn Crisostomo). Where necessary, 
corrections were made during the verification process. As with any retrospective review, 
limitations in the dataset were expected. Nevertheless, every attempt was made to ensure that the 
dataset was an accurate representation of the target population. Certain parameters had to be 
cross-verified using secondary data sources.  
Some examples include: 
a) Identifying primary infection using laboratory cultures with physician diagnosis 
b) Identifying positive infection using WBC counts or identifying fever 
c) Adverse drug event diagnosis confirmed by treatment with corticosteroids, 
antihistamines or in the case of seizure using anti-seizure medication. 
For interpretation of clinical, statistical and pharmacoeconomic findings the following 
disciplines were routinely consulted: 
a) Microbiologist  
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b) Infection control physician  
c) Gastroenterologist  
d) Quality Management Physician  
e) Clinical Pharmacist  
f) Biostatistician  
 
3.13. Bias and Limitations 
Bias may have been introduced in the following ways: 
a) Studies that do not incorporate randomization and blinding may be subjected to bias. 
b) The ICU clinical pharmacists were aware of the higher utilization of MEM.  
c) PI was aware of the unpublished review that estimated a cost saving by utilizing IC 
instead of MEM.  
d) Physicians were aware of a case of seizure with IC and showed preference to use MEM. 
e) National costs of drugs and procedures were used, some companies may offer discounts. 






To minimize the chance of bias the following steps were taken 
a) A clearly defined population that have the same risk of developing the outcome of 
interest. The population expressed in this study reflects real world patients that one would 
encounter in any hospital in Saudi Arabia. 
b) Results were expressed as average daily costs, so as to limit the impact of differences in 
the average LOAS. 
c) National Costs may be generalized to other institutions in Saudi Arabia and may 
represents a more standardized approach to costing data, increasing external validity. 
d) Equivalence studies were evaluated for robustness so as to prove clinical equivalence, 
and those studies which did not show equivalence were considered and balanced against 
the predominant viewpoint. 
e) Diagnosis was verified at various levels including laboratory data, clinical records and 
physician diagnosis. 
f) An independent pharmacist was selected to verify all data collected. If the PI showed any 
bias the independent double check was implemented to rectify any oversight. 
3.14. Ethics  
The protocol received approval from the King Abdullah International Medical Research Centre 
(reference number RRE12/011) (Appendix 1) eastern region of Saudi Arabia, as well as the 
Biomedical Research Ethics Committee at the University of Kwa-Zulu Natal in South Africa 
(reference number  BE: 273/13). (Appendix 2) 
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The information sought was not sensitive in nature, allowing King Abdulaziz International 
Medical Research Center ethics committee approval.  The review of subject’s information was 
only limited and no harm to the subject’s status, employability or insurability could occur. The 
Biomedical Ethics Research Committee of the University of Kwa-Zulu Natal provisionally 
approved the proposal pending several queries. Following resolution of these queries final 
approval was obtained. 
3.15. Storage of Data 
The master list (electronic record) was kept till the final analysis of the data following which the 
identification of all patients was deleted from the file. During the study period and analysis, the 
master list was kept in a secured locked cabinet in the pharmacy director’s office. The master list 
data collection sheets process was then valued in Saudi Riyals and exported to SPSS for 
statistical analysis. Principal Investigator (PI) kept the list and was shared with the data collector 
(Analyn Crisostomo). Only the PI had access to the file. Following the completion of collection 
of data and primary analysis, all the identification parameter such as medical record number was 




CHAPTER 4: RESULTS 
4.1. Introduction 
This chapter provides analytical and descriptive data of the findings. It includes patient 
characteristics, length of hospital stay, clinical findings and economic outcomes. Primary 
outcomes considered were the pharmacoeconomic impact of IC and MEM. Costing data 
represents the institutional perspective and includes resource costs. Secondary outcomes reported 
include clinical and safety findings. Raw data was provided by the hospital information 
management department using the electronic and paper-based patient records. The population 
represented patients that are eligible for treatment at the King Abdulaziz National Guard 
Hospital in Saudi Arabia. No data from the private sector was used in this study. Therefore, the 
data represents a government costing perspective. 
4.2. Overview of Data Management 
An account of the data collection is necessary in providing a background of the sample selected 
and outcomes in this study. The data included any patient with mild to moderate bacterial 
infections with IAI, SSI, LRTI, UTI and sepsis. The data is not representative of patients with 
meningitis, pregnant patients or paediatric patients. Patients with mild to moderate renal 
impairment were considered in the study as these may add to costs. The primary infection was 
reported by the diagnosing physician using the criteria outlined in the method of this study. Some 
patient days had to be corrected and 1 patient diagnosis was rectified after confirming with the 
records in the patient file, patient history and laboratory findings. In cases where the primary 
infection was not clearly identified in the electronic record, the paper-based physician notes were 
used and verified by the parameters defined earlier in the study. A total of 44 patients receiving 
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IC and 44 receiving MEM could be evaluated clinically, as shown in Figure 5. The plan was to 
include 50 patients in each group from 1 January 2012 until 31 December 2012. However it was 
found that only 45 patients on IC could be used for this study, due to the limited usage of the 
drug. MEM was used much more frequently, however only 44 patients were finally selected due 
to the inclusion and exclusion criteria. Furthermore, one file in the IC group and one file in the 
MEM group could not be accessed as it was locked by medical records. Seven patients did not 
meet the study criteria. Patients excluded from the study were due to: 
a) One patient diagnosed with meningitis 
b) One patient found to be pregnant 
c) One patient was less than 18 years old 
d) Two files were locked by Health Information Management Department  
e) Two patients with only a single dose given and drug discontinued. 
Statistical analysis was done with consultation of the King Abdullah International Medical 
Research Center, Department of Biostatistics using SPSS version 21. 
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Figure 5 - Schematic representation of sample 
 
4.3. Baseline Characteristics 
Baseline characteristics are summarized in Table 13. Independent sample T-tests showed no 
significant difference in baseline characteristics in terms of mean age, weight and height. The 
Chi-Square test showed no significant difference in gender between the groups.  
 Table 13 - Baseline characteristics 
 IC (n = 44) MEM (n = 44) p value 
Mean Age in years (SD) 65.64 (19.04) 64.11 (21.28) 0.724 
Mean weight in kg (SD) 71.31 (15.81) 68.80 (21.92) 0.538 
Mean height in cm (SD) 159.32 (11.15) 157.82 (10.06) 0.509 
Male (%) 21 (47.73%) 20 (45.45%) 0.831 
Female (%) 23 (52.27%) 24 (54.55%)  
Key: SD = standard deviation 
100 patients with mild to moderate 
















4.4. Number of Hospital Days 
Numbers of hospital days are summarized in Table 14. Although there was a significant greater 
number of mean critical care days in the IC group compared to the MEM group (p = 0.030), the 
mean number of step-down days showed no significant difference (p = 0.375). No statistically 
significant differences were seen in mean general ward days or in the mean length of antibiotic 
stay (LOAS), as shown in Figure 4.  
Table 14 - Hospital days 
  IC 
(n = 44) 
MEM 
(n = 44) 
p 
value 
Mean CCU days (SD) 13.93 (19.11) 6.86 (9.40) 0.030 
Mean Step-down Days (SD) 4.23 (5.39) 3.25 (4.89) 0.375 
Mean general ward days (SD) 10.64 (18.49) 13.66 (20.66) 0.472 
Mean LOAS (SD) 11.18 (6.34) 9.57 (5.67) 0.212 
Key: IC = Imipenem/ cilastatin, MEM = meropenem, CCU = critical care days; SD = standard deviation;  
LOAS = length of antibiotic stay 
Figure 6 - Mean hospital days 
 




























4.5. Clinical Characteristics 
Clinical success rates (as defined in section 3.8. and 3.10.1.) are shown in Table 15, and were not 
statistically different between IC and MEM (p = 0.661). Independent sample T-test showed no 
significant differences between IC and MEM in terms of mean peak temperature (in degrees 
Celsius) recorded (p = 0.597) and mean WBC (109L) recorded (p = 0.401). Chi-square test 
showed no significant difference in renal function between the groups. Similarly the numbers of 
infections between the groups were not significantly different, as depicted in Figure 7. 
Table 15 - Clinical characteristics 
 IC (n = 44) MEM (n = 44) P value 
Clinical Success 26 (59.1%) 28 (63.6%) 0.661 
Mean Peak Temperature in oC (SD) 37.98 (0.82) 37.89 (0.78) 0.597 
Mean WBC 109 L (SD) 19.27 (10.89) 22.57 (23.44) 0.401 
Normal renal function 35 (79.5%) 34 (77.3%) 0.796 
Moderate renal impairment 9 (20.5%) 10 (22.7%) 0.796 
Number of positive Skin Infections 7 (15.9%) 7 (15.9%) 0.99 
Number of positive Sepsis cases 13 (29.5%) 16(36.4%) 0.496 
Number of positive IAIs  5 (11.4%) 3 (6.8%) 0.458 
Number of positive LRTIs  9 (20.5%) 7 (15.9%) 0.580 
Number of positive UTIs 21 (47.7%) 22 (50.0) 0.831 
Number of positive HAIs 16 (36.4%) 9 (20.5%) 0.098 
Moderate renal impairment with creatinine clearance from 30 to 50 ml/minute and normal renal function greater 






Figure 7- Site and number of infections 
 
Key: IAI = intra-abdominal infection; LRTI = lower respiratory infection; UTI = urinary tract infection; HAI = 
hospital acquired infection 
4.6. Adverse Drug Events (ADEs) 
Gastrointestinal ADEs occurred in 1 (2.3%) of the patients on IC versus 3 (6.8%) of the patients 
on MEM. These ADEs included nausea, vomiting and diarrhoea, as well as any Clostridium 
difficile culture found immediately after initiation of the medicine confirmed. This was 
confirmed by any supportive measure taken for treatment, such as administration of oral 
vancomycin. General ADEs occurred in 1 (2.3%) patient on IC and 1 (2.3%) patient on MEM. 
General ADEs took into account skin reactions, rash, pruritus, urticaria, erythema multiforma, 
and Stevens-Johnson syndrome. Laboratory ADEs occurred in 5 (11.4%) patients in the IC group 
versus 6 (13.6%) patients in the MEM group. One case of seizure associated with IC was 
documented. It was noted that the case of seizure occurred in a high-risk patient with moderate 
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Table 16 - Adverse drug reactions (ADEs) 
  IC 
(n = 44) 
MEM 
(n = 44) 
P 
value 
Gastro-intestinal ADE  1 (2.30%) 3 (6.80%) 0.616 
General ADE 1 (2.30%) 1 (2.30%) 0.99 
Laboratory ADE 5 (11.4%) 6 (13.60%) 0.747 
Seizure 1 (2.30%) 0 (0%)   0.99 
 
4.7. Hospital Resources 
The number of resources used was expected to be higher in the IC group due to the higher 
number of critical care days in this group. Utilisation of key personnel resources is shown in  
Table 17 - Personnel  
   IC 
(n = 44) 
MEM 
(n = 44) 
P value 
Mean number of Consultant Visits (SD) 24.68 (20.96) 18.00 (14.89) 0.088 
Mean number of Physician Visits (SD) 40.93 (41.68) 21.93 (18.53) 0.007 
Mean CCU Nurse days (SD) 13.93 (19.11) 6.86 (9.40) 0.030 
Mean General ward Nurse days (SD) 14.86 (19.49) 16.91 (21.56) 0.642 
Mean Pharmacist minutes (SD) 620.11 (409.78) 392.05 (297.96) 0.004 
Mean Pharmacy Aide minutes (SD) 620.11 (409.78) 392.05 (297.96) 0.004 
Administration Sets (SD) 41.34 (27.32) 25.14 (17.13) 0.001 
Key: SD = standard deviation; CCU = critical care days. Mean visits are expressed per patient 
The mean number of consultant visits was not significantly higher in the IC group than the MEM 
group (p = 0.088). The mean number of physician visits was higher in the IC group compared to 
the MEM group (p = 0.007), as were the mean ICU nurse days (p = 0.030). The mean general 
ward nurse days were not statistically different (p = 0.642). The mean pharmacist time included 
the time to process the order and included technician preparation time of the intravenous 
minibag. It was estimated that each minibag takes 15 minutes to prepare. The mean pharmacist 
time (in minutes) was significantly higher in the IC group compared to the MEM group (p = 
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0.004). The pharmacy aide time considered the time to deliver the study drug to the units to be 
15 minutes per item. The mean pharmacy aide time appeared significantly higher in the IC group 
compared to the MEM group (p = 0.004). The mean number of administration sets used in the IC 
group was also significantly higher than in the MEM group (p=0.001). 
4.8. Economic Evaluation 
Resource utilization costs are listed in Table 18 as the mean resource cost per day. Comparison 
of the mean daily costs using independent sample –T tests demonstrated no significant difference 
in terms of mean daily CCU and step-down costs. Mean CCU days for the IC group cost SAR 
1,022.73 (95% CI 807.86 to 1,237.59) and for the MEM group were SAR 784.09 (95% CI 
553.67 to 1014.51), These mean costs were significantly different (p = 0.13). The mean step-
down costs were not significantly different (p = 0.99). Mean general ward costs were 
significantly lower in the IC group than the MEM group (p = 0.016). A significant lower 
medicine acquisition vial cost was observed for IC (SAR 250.63, 95% CI 238.06 to263.20) 
compared to MEM (SAR 393.48, 95% CI 366.12 to 420.84) (p < 0.001). However there was a 
significantly higher cost attached to administration sets in the IC group (SAR 39.16, 95% CI 37.2 
to 41.13) than in the MEM group (SAR 28.00, 95% CI 26.61 to 29.39) (p < 0.001). Mean daily 
laboratory costs in the IC group were not significantly different when compared to the MEM 
group (p =0.379), however the costs of mean daily laboratory cultures were significantly lower in 
the IC group compared to the MEM group (p = 0.014). Mean CCU consultations costs were not 
significantly different between the groups (p = 0.13), nor were mean daily GW consultations (p = 
0.939) and staff physician consultations (p = 0.056).  
Mean CCU daily nursing costs were not significantly different (p = 0.13), nor were mean daily 
GW nursing costs (p = 0.956) However, mean daily pharmacists costs were significantly higher 
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in the IC group (SAR 64.08, 95% CI 60.87 to 67.30) compared to the MEM group (SAR 46.82, 
95% CI 43.57 to 50.08) (p < 0.001). Mean daily pharmacy aide costs were also significantly 
higher in the IC group than the MEM group (p < 0.001). There was no difference in the mean 
costs of ADEs between the two groups (p = 0.333). 
Overall there was no difference in the mean total daily costs between IC (SAR 4784.46, 95% CI 
4140.68 to 5428.24) and MEM (SAR 4390.14, 95% CI 3785.82 to 4994.45) (p = 0.37), as shown 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 8 - Resource utilization costs 
 






















































4.8.1. One-way sensitivity analysis 
One-way sensitivity analysis was performed in Microsoft ® Excel by varying the mean cost of 
each parameter of IC and MEM. A 20% variation from the mean parameter cost produced the 
following outcomes with IC: 
The mean parameter cost was increased and decreased to assess those parameters with the 
greatest impact on the total costs.  Changes in the base value (IC = SAR 4,784.46 and MEM = 
SAR 4,390.13) were noted.  
Table 19 – One-way sensitivity analysis with IC  
Parameters Low High % change 
CCU days 4,579.91 4,989.00 4.28 
Step-down days 4,669.91 4,899.00 2.39 
GW days 4,710.02 4,858.89 1.56 
Vials 4,734.33 4,834.58 1.05 
Admin Sets 4,776.62 4,792.29 0.16 
Laboratory tests 4,603.46 4,965.45 3.78 
Laboratory cultures 4,767.13 4,801.78 0.36 
CCU consult 4,648.09 4,920.82 2.85 
GW Consult 4,743.40 4,825.51 0.86 
Staff Physician 4,731.56 4,837.35 1.11 
CCU Nurse 4,743.55 4,825.37 0.85 
GW Nurse 4,765.88 4,803.03 0.39 
Pharmacist 4,771.64 4,797.27 0.27 
Pharmacy Aide 4,780.18 4,788.73 0.09 
ADE 4,784.25 4,784.67 0.00 
 
One-way sensitivity analysis with a 20% change in IC parameters shows that the parameters, 
which exerts the greatest change in the mean total cost are: 
a) CCU days with a 4.28% change in the total cost  
b) Laboratory tests with a 3.78% change in the mean total costs  
c) CCU consultation charges with 2.85% change in the total costs 
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d) Step-down days with a 2.39% change in the total costs 
e) GW days with a 1.56% change in the total costs 
 
Figure 10 - One way sensitivity analysis with IC (mean value = SAR 4,784.46) 
 
The parameters which least affected the total costs in the IC group were: 
a) ADE with 0.004% change in the mean total cost 
b) Pharmacy Aide with 0.09% change in mean the total cost 
c) Administration sets with a 0.16% change in mean the total costs. 
d) Pharmacists with a 0.27% change in the mean total cost 
e) Laboratory cultures with a 0.36% change in the mean total cost 
f) GW nursing with a 0.39% change in the mean total cost 
One-way sensitivity analysis with a 20% change in MEM parameters shows that the parameters, 
which exerts the greatest change in the mean total cost are: 
a) CCU days with a 3.57%% change in the mean total cost  
b) Laboratory tests with a 3.47% change in the mean total costs  









Mean Daily Cost (SAR)
20% decrease 20% increase
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c) CCU consultation charges with 2.38% change in the mean total costs  
d) Step-down days with a 2.61% change in the mean total costs 
e) GW days with a 2.12% change in the mean total costs 
 
A 20% variation from the mean parameter cost produced the following outcomes with MEM: 
Table 20 - One-way sensitivity analysis with MEM 
MEM 20% decrease 20% increase % change 
CCU days 4,233.31 4,546.95 3.57 
Step-down days 4,275.58 4,504.67 2.61 
GW days 4,296.95 4,483.31 2.12 
Vials 4,311.43 4,468.82 1.79 
Admin Sets 4,384.53 4,395.73 0.13 
Laboratory tests 4,237.86 4,542.39 3.47 
Laboratory cultures 4,364.20 4,416.06 0.59 
CCU consult 4,285.58 4,494.67 2.38 
GW Consult 4,350.03 4,430.22 0.91 
Staff Physician 4,347.02 4,433.24 0.98 
CCU Nurse 4,358.76 4,421.49 0.71 
GW Nurse 4,371.49 4,408.76 0.42 
Pharmacist 4,380.76 4,399.49 0.21 
Pharmacy Aide 4,387.01 4,393.25 0.07 
ADE 4,389.37 4,390.88 0.02 
 









Figure 11- One way sensitivity analysis with MEM (mean value = SAR4,390.13) 
 
 
The parameters which least affected the total costs in the MEM group were: 
a) ADE with 0.02% change in the mean total cost 
b) Pharmacy Aide with 0.07% change in the mean total cost 
c) Administration sets with a 0.13% change in the mean total costs 
d) Pharmacists with a 0.21% change in the mean total cost 
e) GW nursing with a 0.42% change in the mean total cost 
f) Laboratory culture with 0.59% change in the mean total cost 
 
4.8.2. Threshold Analysis 
A threshold analysis was performed on parameters so as to assess the value at which our 
conclusions change. The value of the parameter was being sought that agreed with our initial 
assumption that IC is less costly than MEM. It was assumed, using independent sample T-test 









Mean Daily Cost (SAR)
20% decrease 20% increase
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comparison of the mean, with  p <0.05, that the conclusion will change in favour IC as being 
significantly less costly, if the total costs were below SAR 3,795.00. Our initial unpublished 
study assumed that acquisition costs significantly impacts the total health care costs. Using the 
parameters of the acquisition costs, the input value was varied to assess the threshold at which 
the total costs in the IC group would be less than SAR 3,795.00. The parameters included vial 
costs, ADEs, administration sets and pharmacists’ costs.  
Figure 12 - Impact of variations in ADEs, vial costs and pharmacists costs 
 
 The threshold analysis found that variations in ADEs, vial costs, administration costs and 
pharmacists’ costs did not affect the conclusion even if the input value of each of the acquisition 
































Table 21 - Impact of variations in ADEs, vial costs, administration sets and pharmacist 
costs on total costs 
Cost 
Intervention 
ADEs Vial Cost Administration 
 Sets 
Pharmacist Costs 
-1,000 3,783.41 3,533.83 3,745.30 3,720.38 
-750 4,033.41 3,783.83 3,995.30 3,970.38 
-500 4,283.41 4,033.83 4,245.30 4,220.38 
-250 4,533.41 4,283.83 4,495.30 4,470.38 
0 4,783.41 4,533.83 4,745.30 4,720.38 
250 5,033.41 4,783.83 4,995.30 4,970.38 
500 5,283.41 5,033.83 5,245.30 5,220.38 
750 5,533.41 5,283.83 5,495.30 5,470.38 
1,000 5,783.41 5,533.83 5,745.30 5,720.38 
1,250 6,033.41 5,783.83 5,995.30 5,970.38 
 
Acquisition costs threshold values for each parameter was less than 0 (Table 22).  




Vial costs -738.83 
Administration sets -950.30 
pharmacist cost -925.38 
 
Threshold analysis was done on those parameters that had the greatest effect on the total cost of 
treatment. The value was being sought of each parameter that would change our conclusion i.e. 
the point at which IC becomes less costly than MEM. The total value was once again set to SAR 
3,795.00. Parameters included was hospital days (CCU, step-down and GW), as these were 
found to impact total costs the most. 
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Figure 13 - Impact of variations on CCU, step-down and GW costs 
 
The threshold analysis found that variations in step-down costs and GW costs did not affect the 
conclusion even if the input value of each of the acquisition costs parameter was set at SAR 0.00. 
However the threshold value of CCU was SAR 33.27. Input and output values are listed in 
Table 23. 




-1,000 2,762 3,211.73 3,412.30 3,795.00 
-750 3,012 3,461.73 3,662.30 3,795.00 
-500 3,262 3,711.73 3,912.30 3,795.00 
-250 3,512 3,961.73 4,162.30 3,795.00 
0 3,762 4,211.73 4,412.30 3,795.00 
250 4,012 4,461.73 4,662.30 3,795.00 
500 4,262 4,711.73 4,912.30 3,795.00 
750 4,512 4,961.73 5,162.30 3,795.00 
1,000 4,762 5,211.73 5,412.30 3,795.00 































































Acquisition costs threshold values for each parameter was less than 0, except CCU which was 
SAR 33.27. Threshold values for hospital days are listed in Table 24. 
 
Table 24 - Threshold value of hospital days at which IC is less costly than MEM 
Parameter Threshold 
CCU days 33.27 
Step-down days  -416.73 
GW days -617.30 
 
Costs related to primary infection and superinfections 
Other costs related to primary infection and superinfections are listed in Table 25. This includes 
add-on antibiotics, previously failed antibiotics and antifungals used to treat either the primary 
infection or superinfections. Independent sample T-tests found no significant difference in mean 
daily costs between antifungals, ancillary antibiotics or previous failed antibiotics between the 
two groups. 
 
Table 25 - Costs related to primary infection and superinfections 
Mean Cost/day IC MEM  
 Mean SD Mean SD P value 
Antifungal 80.05 250.72 139.88 430.24 0.428 
Ancillary Antibiotics 189.24 211.07 207.58 196.30 0.674 






CHAPTER 5: DISCUSSION 
5.1. Introduction 
This chapter will discuss the results of this study within the context of carbapenem usage in a 
300-bed government hospital in Saudi Arabia, and also in relation to the available published 
literature. It will discuss the setting of the study; baseline characteristics focusing on the primary 
objectives of the study (cost minimization analysis).  
Several factors prompted the need for a pharmacoeconomic evaluation of IC and MEM. These 
included an institutional review of antimicrobial restriction, and concerns about usage and costs. 
Most importantly, the acquisition costs of IC were noted to be less than those for MEM 
(SAR70.4 versus SAR 151.26 per vial). In addition, published pharmacoeconomic evaluations 
are limited in Saudi Arabia (4). To our knowledge, no published pharmacoeconomic evaluations 
comparing IC and MEM in adult patients had been conducted in Saudi Arabia. There have been 
several international pharmacoeconomic evaluations done (1, 2, 37) with conflicting results. 
Using data based on the local perspective therefore had the potential to provide insight into the 
factors influencing local practice and medicines selection. Government institutions in Saudi 
Arabia, providing free medical treatment, may adopt similar costing strategies that are unique to 
this region.  
A retrospective review of 100 files were planned, but only 88 patients records met the study 
criteria. The type of research was based on staffing, budgeting constraints, and the small sample 
size. However, a double-blinded randomized control trial would have been optimal. The number 
of patients on IC, that met the study criteria, was limited to only 45 for the year 2012. In addition 
one file could not be retrieved by the hospital information management department, leaving 44 
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clinically evaluable charts. MEM patients numbered 44 with 6 charts not meeting the study 
criteria as mentioned in the method section above. The review included adult patients (≥ 18 
years), as the paediatric population weights and dosing vary considerable. The patients with 
moderate to severe infections with SSI, IAI, LRTI, sepsis, UTI and HAI were considered, as 
these are the main indications of carbapenems approved by the institution guidelines. 
Furthermore, a wealth of literature supports the use of IC and MEM for the indications 
described. In addition, the literature review provides evidence showing that IC and MEM share 
similar efficacy and tolerability profiles. Bacterial meningitis was not included as this group is 
at-risk for seizures. Pregnant patients were also excluded due to the unpredictable 
pharmacokinetic parameters in this population. In order to minimize bias a clearly defined 
population was used, that have the same risk of developing the outcome of interest.  
A cost-minimization analysis was considered based on the clinical equivalence studies above, 
assuming similar efficacy and safety profiles between IC and MEM cited in the literature review. 
Thus equivalency studies were presented to reinforce our assumption of clinical equivalency. 
Institutional antimicrobial guidelines(15)  recommend IC at a dose of 0.5 to 1 gram every 6 
hours and MEM at a dose of 1 gram every eight hours for mild to moderate infections. The 
United States FDA recommendations (33, 34), reinforced by the literature review (36) supports 
the institutional guidelines. Therefore the study dosage of IC 500mg q6h and MEM 1gram q8h 
was selected. The cost-minimization was performed following a previously unpublished 
institutional review that suggested a substantial saving, had the institute enforced the 
antimicrobial restriction guidelines. It was suggested that an interchange program of MEM with 
IC would drive down costs. On the other hand, physicians showed preference to MEM, due to 
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the apparent risk of seizures with IC (60). This has led to an increased usage of MEM, 
substantially impacting the hospital budget. 
 
5.2. Findings 
5.2.1. Comparative review 
The approach used was to seek evidence from clinical trials of the clinical equivalency between 
IC and MEM in terms of efficacy and safety. A literature review of 18 studies comparing IC to 
MEM concluded that IC is as effective and well tolerated in mild to moderate infections. None of 
the 18 studies included a non-inferiority study design. The six studies which showed superiority 
of either agent were not considered to alter this overall judgment. The justification for this 
conclusion was provided in section 2.3.8. The studies by Edwards et al. (2, 49) were not in 
agreement with the conclusions drawn in the 18 studies that showed clinical equivalence.  
Four studies showed that IC was significantly less costly than MEM. Only one well-designed 
pharmacoeconomic study by Attanasio et al. (1) had well described costing data measuring direct 
costs. Details of the costing approach for two studies were not clear, while the third measured 
acquisition costs. One study by Edwards et al. (2) applying pharmacoeconomic principles found 
MEM to be significantly less costly than IC. 
Evidence retrieved suggests the following:  
a) Literature supports the rationale of the study dose of IC 500mg q6h and MEM 1gram q8h 
b) No significant difference in clinical, bacteriological and adverse effects of IC and MEM 
in patients with IAI 
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c) No significant difference in clinical, bacteriological and adverse effects of IC and MEM 
in patients with SSI 
d) IC and MEM showed similar efficacy and safety profiles in patients with respiratory tract 
infections 
e) IC and MEM showed no significant difference in clinical or bacteriological outcomes in 
patients with UTI 
f) IC is as well tolerated and effective as MEM in patients with sepsis 
g) Four RCTs showed similar safety profiles between IC and MEM 
 
Based on the above; IC at a dose of 500mg q6h (cost = SAR 281.60 per day) is an attractive 
alternative to MEM 1gram q8h (cost = SAR 453.78 per day), particularly in mild to moderate 
infections. These studies show that both drugs share similar clinical efficacy and tolerability 
profiles. Carbapenems should be avoided in elderly patients, patients with low body weight, at 
risk of CNS disease, history of seizure and renal dysfunction. Our review was in agreement with 
the 18 studies showing that IC is as effective and well tolerated as MEM. However, this study 
was not in agreement with the pharmacoeconomic conclusions in the studies above. The 
economic evaluation is discussed in section 5.1.6. It must be further mentioned that future 
research might access studies using a formal non-inferiority approach rather than the assumed 
equivalency approach that was used in the studies retrieved. 
5.2.2. Baseline Characteristics  
Baseline characteristics in our study were not significantly different in terms of the mean age, 
weight and height (Table 13). A significant greater number of CCU days in the IC group was 
found when compared with the MEM group (13.93 vs. 6.86, p= 0.030). Higher number of 
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critical care days was associated with higher total costs in the IC group. Outliers were identified 
in the IC group with 1 patient in the ICU as much as 102 days. The intensive care pharmacist’s 
intervention (interchanging MEM with IC) resulted in more patients using IC in CCU compared 
to the general wards. PTC recommendations were implemented to reduce costs. Our hospital 
does not have clinical pharmacists in the step-down units and general wards resulting in much 
more erratic use of MEM in these areas. However overall costs per day were not affected 
significantly in the critical care areas. There were no significant difference in step-down days 
and GW days in both groups. 
5.2.3. Clinical efficacy and safety outcomes 
As this is a cost-minimization analysis, the assumption of equivalent efficacy was demonstrated 
by literature retrieved and cited and not the outcomes of patients treated, whose cost data are 
being sought in this study. Nevertheless the clinical efficacy and safety outcomes found in this 
study agreed with the studies cited in the literature review chapter. This study focused on patients 
diagnosed with skin infections (SSI), intra-abdominal infections (IAI), respiratory tract 
infections, urinary tract infections (UTI), hospital acquired infections (HAI) as well as those with 
sepsis. Equivalency studies with a pharmacoeconomic evaluation showed IC to be less costly 
than MEM (1, 37, 40). It was noted that Edwards et al. (2) did not agree with this finding.  
Clinical success rates (59.1% in IC group versus 63.6% in the MEM group, p = 0.661) were not 
significantly different. The number of positive infections appeared similar.  LOAS were not 
statistically different in both groups (mean IC =11.18 and MEM = 9.57, p = 0.212). The clinical 
efficacy data between IC and MEM in this study agreed with the studies cited in the literature 
review. IC and MEM showed no difference in their clinical efficacy 
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The overall ADEs were not significantly different between the groups. It was found that ADEs 
were under reported when compared to published studies (54). In this regard ADEs was 
confirmed by objective parameters. These include initiation of anti-seizure medication if the 
patient had a seizure, corticosteroid and anti-histamines for rash and therapies for antibiotic 
associated diarrhoea. Although more patients had gastrointestinal ADEs in the MEM group, it 
was not significantly different when compared to IC. These were mainly antibiotic associated 
diarrhoea after C. difficle culture was taken. Antibiotic diarrhoea was confirmed by comparing 
the patient record to the physician notes or the patients were started on supportive measures or 
therapies like vancomycin oral. Other objective measures included laboratory ADEs. One patient 
on IC had a seizure associated with IC administration. This concern among health care workers 
prompted the avoidance of IC in our hospital. One study (3), which is often quoted to highlight 
the seizures of IC may have also influenced the poor usage of IC. The study suggests that IC may 
be associated with drug-related seizure events. It must be pointed out that Hoffman et al. (54) 
found no difference in seizure rates between IC and MEM, and that elderly patients, patients 
with low body weight, at risk of CNS disease, history of seizure and renal dysfunction appears to 
be associated with increased risk of drug related seizure The patient was at risk for seizures as 
she was geriatric patient with moderate renal impairment. This study excluded patients with 
bacterial meningitis due to this population being at risk for seizures. In addition our hospital 
guidelines (15) does not advocate its use in those at seizure risk and patients with poor kidney 
function. Our study did not show significant difference in in ADE’s between IC and MEM, 




5.2.4. Hospital resources 
The number of physician visits were significantly higher in the IC group when compared to 
MEM (mean IC= 40.93, SD = 41.68 versus mean MEM = 21.93, SD 18.53). This was attributed 
to more CCU days found in the IC group which necessitated more physician visits. Similarly 
more CCU nurse days were found in the IC group, related to more patients in the IC group in 
critical care areas. As expected the mean pharmacists’ time (in minutes) was significantly higher 
in the IC group compared to the MEM group (mean IC = 620.11, SD 409.78 versus mean MEM 
= 392.05, SD = 297.96). The institute prepares both antibiotics in the intravenous admixture 
room. Both antibiotics are prepared as a late-mix just before the dose is due. IC was given 4 
times daily while MEM was given 3 times daily.  The delivery by the pharmacy aide showed 
more delivery time with IC compared to MEM, again this is attributed to the 4 times daily versus 
3 times daily of IC and MEM respectively. For the same reason, more administration sets and 
minibags were required for the IC group. The results clearly demonstrate that significantly more 
time is required per day to prepare IC compared with MEM. Overall more hospital resources are 
required in the preparation, dispensing and administration of IC compared to the MEM group, 
except in mean number of consultant visits and mean number of nurse general ward visits.  
5.2.5. Costing 
The October 2013 business centre and SFDA Human Drug List pricing was used corresponding 
to the final ethics approval obtained in October 2013. In addition, the most updated costing was 
being sought. A standardised approach to the pricing was used rather than the actual hospital 
cost. Standardised figures are more generalizable to other government health sectors, as these 
include the standard list prices. The prices used were indicative of the generic medicine brands 
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available at our institution. Costs per day were calculated rather than total cost per patient so as 
to limit the impact of differences in LOAS. 
 
5.2.6. Economic Evaluations 
Total hospital days, especially the total CCU days in the IC group was significantly higher. This 
was attributed to the clinical pharmacist’s intervention of interchanging MEM with IC. The 
greater usage of IC with more “sicker patients” affected the number of hospital days. The longer 
CCU days was believed to influence costing, especially in the IC costs. The cost per day of a 
CCU day is highest (SAR 1500) compared to a step-down (SAR 900) unit or a general ward 
(SAR 500). Patients varied significantly in regard to the number of CCU days. Daily costs would 
allow comparison of the two antibiotics while minimizing bias due to length of hospital stay. In 
this regard, all costs were reflected as cost per day.  
Independent sample T-tests showed no significant difference in terms of mean daily hospital 
costs in CCUs (IC = SAR 1,022.73, 95% CI [807.86, 1,237.59] and MEM = SAR 784.09, 95% 
CI [553.67, 1014.51], p = 0.13); and step-down costs (IC = SAR 572.73, 95% CI [439.58, 
705.88] and MEM = SAR 572.73, 95% CI [439.58, 705.88], p = 0.99). However the GW costs in 
the IC group was significantly lower in the IC group (SAR 372.16, 95% CI [305.83, 438.49] 
compared to MEM at SAR 465.91, 95% CI [427.15, 504.67], p = 0.016).  Although total CCU 
costs were higher, cost per day was not statistically different between the two groups, except in 
the GW days. More patients in the MEM group spent a greater number of days in the GW unit, 
which drove up mean costs in this group. 
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The mean total daily costs of vials in the IC group were much lower than MEM (SAR 250.63 vs. 
393.48). This was expected as the cost of a vial of IC = SAR 70.4 versus MEM = SAR 151.26. 
IC given 4 times daily would result in daily costs of SAR 281.60 versus MEM given 3 times 
daily at SAR 453.78. The mean costs in our study were mean costs reflecting dose changes as 
well. In the institution, previous unpublished study, this difference in acquisition costs amounted 
to a significant saving of more than SAR 2 million riyals for the organization. This makes IC an 
attractive choice as a carbapenem in patients with moderate to severe infections. However the 
institutional review did not include resource costs associated with the primary infection. Our 
study included personnel costs, administration costs, length of hospital stay, laboratory charges, 
delivery costs and costs related to ADEs. The administration sets costs were higher in the IC than 
MEM (SAR39.16 vs. SAR 28.00). Pharmacy preparation time and costs was significantly higher 
in the IC group than the MEM group (SAR 64.08 vs. SAR 50.08). Pharmacy aide delivery time 
and costs were much higher in the IC group compared to the MEM group (SAR 21.36 vs. SAR 
15.61). The administration, preparation, dispensing and delivery costs were related to the 
frequency of the dosing times; with IC given every 6 hours versus MEM given every 8 hours. As 
a result costs were higher in the IC group. Overall the acquisition costs of IC were significantly 
lower in the IC group, while costs in the preparation, dispensing, administration sets, and 
deliveries were higher in the IC group. No significant difference was found in terms of average 
daily nursing costs between the two groups. The business centre costs for nursing were not 
related to the number of patient visits. Consultant, physician and nursing costs were not affected 
by the frequency of administration costs; rather they were affected by the number of CCU days, 
whereas administration sets, pharmacy aide delivery time and pharmacists’ time were related to 
the frequency.  
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Laboratory tests mean costs per day were not significantly different between the groups. The 
laboratory cultures mean costs per day was significantly higher in the IC group. This may be 
attributed to the higher number of CCU patients that require more critical care and more cultures.  
Despite significant differences in acquisition costs, laboratory culture costs, pharmacist and 
pharmacy aide costs, the total average costs per day was not significantly different between the 2 
groups (SAR 4,784.46 IC and SAR 4,390.13 MEM, p = 0.370). Our review may have agreed 
with literature review in terms of the clinical and safety outcomes, we found no difference in the 
overall mean total daily costs between the 2 drugs. 
The studies by Attanasio et al. (1), Beketov et al. (40) and Zhanel et al. (36) showed both agents 
to be clinically effective and showed IC to be less costly. These three studies only considered 
patients with IAI, whereas our study included a larger definition as outlined in the methods 
chapter. Our study was in agreement with similar clinical efficacy; however the total costs were 
not significantly different between the two groups which was similar to the findings of Badia et 
al. (37). Attanasio et al. (1) included direct costs such as diagnostic procedures, drug acquisition 
and administration, management of adverse events and hospitalization. Our study included 
similar direct costs as well as pharmacist time and delivery costs. Zhanel et al. (36) showed 
similar cost-effectiveness as Attansio et al. (1), however the details of the cost analysis were not 
available.  
The greater number of CCU days in the IC group seems to be the reason for driving up the total 
costs in the IC group. However mean total daily costs were not significantly different. Although 
the costing details for Badia et al. (37) were not available our study was in agreement that there 
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were no significant differences in the total costs between IC and MEM, clinical efficacy and 
safety. 
Other costs related to the primary infections were not significantly different. 
 
Local perspective 
It must be pointed out that some resource costs are unique to the local perspective. These include 
resource costs that are fixed in the institution and not related to the number of patient visits. 
Nursing services costs have daily rates rather than cost per visit. IC requires more frequent 
administration and costs were expected to be higher. However, with fixed costs, this was not 
apparent. Other costs like consumables were also fixed. Most resources were variable and based 
on the number of patient days or related to the frequency of administration. 
Sensitivity Analysis 
A one-way sensitivity analysis varying the resource costs by 20% showed that the mean total 
costs were sensitive to hospital days, laboratory tests and CCU consultations charges (Table 19 
and Table 20). These findings did not support our hypothesis that acquisition costs and costs 
related to administration times play a major role in total daily costs. The sensitivity analysis 
found that ADEs, pharmacy aide delivery costs, pharmacist costs, administration costs, and 
nursing costs were the least sensitive parameters in relation to the total costs. The sensitivity 
analysis sheds light on the factors that influence costing of the primary infection. Our study 
shows that costs related to the LOAS and consultation charges may affect total costs much more 
than acquisition costs or ADE costs.  
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A threshold analysis was performed on the hospital days, acquisition costs and personnel costs. 
The only parameter found to change the conclusion was CCU days. If the CCU value was less 
than SAR 33.27, average total costs of IC would be less costly than MEM. Our conclusion did 




Our study was a retrospective single-cohort study that reflects the practices of our institution.  A 
double blind randomized controlled multi-centre trial would have been optimal. However due to 
the limitations of budgeting and manpower, ethical approval, blinding and randomization could 
not be achieved. Sample size was small. Only 44 patient’s files could be evaluated due to the 
lack of patients prescribed IC and patients that met the inclusion criteria.  
Missing information could have added to the bias; however every effort was made to accurately 
identify missing information. Primary infection was based on the physician diagnosis. Some of 
the files had incomplete documentation and in this case the physician notes had to be consulted 
as defined in the methods section as well as laboratory cultures. Every attempt was made to 
obtain correct diagnosis based on physician notes and definitions above. Two files were 
inaccessible as they were locked by the Hospital Information Management Department for 
review. The ADEs were confirmed using objective parameters. 
The costing of drugs was taking from the SFDA human drug list pricing (8). The cost of 
resources was taken from the hospital’s business centre section. This may not reflect the true 
costs that the institution would pay. Suppliers may offer discounts to government institutions. 
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Experts may argue that the societal perspective may be the only true measure of a 
pharmacoeconomics evaluation as it measures the benefits to the community as a whole. 
However, this study considered the provider perspective so as to provide guidance on hospital 
formularies in the region. 
The PI was aware of the PTC review of IC and MEM as well as the cost-saving interventions. 
The data was double-checked by a second pharmacist to ensure that any oversight was correctly 
rectified.  
Only equivalence studies were being sought (citation bias). A wealth of evidence exists showing 
similar efficacy between the drugs. Some studies have shown differences in terms of efficacy 
and cost-effectiveness; however the perspective of a cost minimization analysis is based 
fundamentally in proving their similarities rather than a difference. Some experts (58) may 
disagree with a cost minimization analysis, however based on the institutional perspective 
antimicrobial Guidelines (15), these two antibiotics are clinically equivalent in terms of efficacy 
and safety, as described in the introduction of this paper.  
Despite these limitations, our study has given insight into the factors influencing hospital budgets 





CHAPTER 6: CONCLUSIONS AND RECOMMENDATIONS 
6.1. Introduction 
The overriding purpose of this study was to find the least costly alternative of 2 therapeutically 
equivalent alternatives (IC 500mg q6h versus MEM 1 gram q8h) in a tertiary care hospital in 
Saudi Arabia. The purpose of this chapter is to conclude and summarise the findings of this study 
and recommend strategies ensuring efficient budget utilization of IC and MEM at our institute. 
To achieve that goal it has become necessary to explore the field of pharmacoeconomics, in 
Saudi Arabia, using cost minimization analysis in an environment that has limited research in 
this field. Studies of this nature could help PTC formulary decision in providing the most 
effective, equitable and efficient services for our population, within the resources entrusted to us. 
In addition to looking at acquisition costs, this study aimed to look at hospital resources and 
personnel costs that influence costs in our setting. Recommendations for future research of IC 
and MEM are also recommended in this chapter.  
6.2. Conclusions 
The outcomes of this retrospective review of 88 adult patients in a tertiary care institute in Saudi 
Arabia, found that although IC acquisition costs is significantly less that MEM, the mean total 
costs per day was not significantly different between IC and MEM. This study supports the PTC 
recommendation of carbapenem selection by restricting MEM to infection control physician 
only. In addition, costs related to frequency of administration times were higher in the IC group 
compared to MEM, however not significantly impacting mean total costs.  This included 
pharmacy aide delivery, pharmacist preparation and administration sets used. 
100 
 
The study showed that those factors with the greatest impact on hospital costs were related to the 
hospital stay, especially CCU days. Mean total costs were also sensitive to CCU consultant visits 
and laboratory cultures associated with CCU admission.  
Threshold analyses found that reduction of CCU day costs was the only factor which could 
change the conclusion; other parameters did not change the conclusion of the study, even if the 
input parameter was SAR 0.00. 
The secondary outcomes agreed with previous findings that IC 500mg q6h is as effective and 
well tolerated as MEM 1 gram q8h. 
Carbapenems should be avoided in elderly patients, patients with low body weight, at risk of 
CNS disease, history of seizure and renal dysfunction. 
This study has shown that while acquisition costs of IC at a dose of 500mg q6h may be less 
costly than MEM 1 gram q8h, mean total costs per day was not significantly different between 
IC and MEM, indicating that medicine costs are only a small element of the overall costs of 








6.3. Recommendations  
The following recommendations are based on the analysis and interpretation of the study. The 
perspective of the recommendations is that of a Saudi Arabian government sector hospital in 
adult patients with mild to moderate infection. 
1. Interchanging MEM 1 gram q8h with IC 500mg q6h reduces cost per day, however this is 
not a major component influencing total daily costs related to the primary infection. 
2. Enforce PTC recommendation of using IC as the first line carbapenem in moderate to 
severe infections 
3. IC 500mg q6h is as effective and well tolerated as MEM 1 gram q8h in moderate to 
severe infections 
4. Carbapenems should be avoided in patients at risk of seizures including elderly patients, 
patients with low body weight, at risk of CNS disease, history of seizure and renal. 
5. More robust pharmacoeconomic studies are needed in Saudi Arabia. It would have been 
optimal if conditions favoured a blinded randomized control trial. Comparative studies 
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